Vyant Bio (VYNT) 10-K 16 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Mar. 01, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	CGIX
Entity Registrant Name	CANCER GENETICS, INC
Entity Central Index Key	1349929
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Accelerated Filer
Entity Common Stock, Shares Outstanding		9,821,169
Entity Public Float			$83.20

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
CURRENT ASSETS
Cash and cash equivalents	$25,554,064	$49,459,564
Accounts receivable, net of allowance for doubtful accounts of 2014 $251,176; 2013 $36,000	5,028,620	1,567,039
Other current assets	1,191,214	864,616
Total current assets	31,773,898	51,891,219
FIXED ASSETS, net of accumulated depreciation	4,446,593	1,264,624
OTHER ASSETS
Security deposits	1,564	1,564
Restricted cash	6,300,000	300,000
Loan guarantee and financing fees, net of accumulated amortization of 2014 $0; 2013 $517,500	0	310,500
Patents	502,767	401,709
Investment in joint venture	1,047,744	987,657
Other investments	38,429	0
Goodwill	2,994,135	0
Total other assets	10,884,639	2,001,430
Total Assets	47,105,130	55,157,273
CURRENT LIABILITIES
Accounts payable and accrued expenses	3,762,567	2,346,240
Obligations under capital leases, current portion	58,950	51,400
Deferred revenue	544,446	199,560
Notes payable, current portion	0	22,298
Line of credit	0	6,000,000
Total current liabilities	4,365,963	8,619,498
Obligations under capital leases	300,385	309,777
Deferred rent payable	347,840	170,789
Line of credit	6,000,000	0
Warrant liability	52,000	594,000
Acquisition note payable	560,341	0
Deferred revenue, long-term	924,850	0
Total liabilities	12,551,379	9,694,064
STOCKHOLDERS' EQUITY (DEFICIT)
Common stock, authorized 100,000,000 and 24,000,000 shares, respectively, $0.0001 par value, 9,821,169 and 9,275,384 shares issued and outstanding as of December 31, 2014 and 2013, respectively	982	927
Additional paid-in capital	112,520,268	106,786,862
Accumulated (deficit)	-77,967,499	-61,324,580
Total Stockholders’ Equity	34,553,751	45,463,209
Total Liabilities and Stockholders’ Equity	47,105,130	55,157,273
Series A Preferred Stock
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock	0	0
Series B Preferred Stock
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock	$0	$0

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accounts receivable, allowance for doubtful accounts	$251,176	$36,000
Loan guarantee and financing fees, accumulated amortization	$0	$517,500
Common stock, shares authorized	100,000,000	24,000,000
Common stock, par value	$0.00	$0.00
Common stock, shares issued	9,821,169	9,275,384
Common stock, shares outstanding	9,821,169	9,275,384
Preferred stock, shares authorized	9,764,000
Series A Preferred Stock
Preferred stock, shares authorized		588,000
Preferred stock, par value		$0.00
Series B Preferred Stock
Preferred stock, shares authorized		2,000,000
Preferred stock, par value		$0.00

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
Revenue	$10,199,387	$6,609,957	$4,301,563
Cost of revenues	8,453,671	4,924,626	3,928,993
Gross profit	1,745,716	1,685,331	372,570
Operating expenses:
Research and development	4,622,526	2,190,204	2,111,947
General and administrative	12,368,739	6,115,035	4,502,424
Sales and marketing	3,963,537	1,841,675	1,398,786
Total operating expenses	20,954,802	10,146,914	8,013,157
Loss from operations	-19,209,086	-8,461,583	-7,640,587
Other income (expense):
Interest expense	-472,820	-2,387,733	-4,701,028
Interest income	73,802	29,693	0
Change in fair value of warrant liability	417,000	4,633,000	7,538,000
Change in fair value of acquisition note payable	198,000	0	0
Loss on debt and warrant restructuring	0	0	-1,862,012
Debt conversion costs	0	-6,849,830	0
Total other income (expense)	215,982	-4,574,870	974,960
Loss before income taxes	-18,993,104	-13,036,453	-6,665,627
Income tax (benefit) provision	-2,350,185	-663,900	0
Net loss	($16,642,919)	($12,372,553)	($6,665,627)
Basic net loss per share (usd per share)	($1.76)	($2.65)	($4.97)
Diluted net loss per share (usd per share)	($1.80)	($3.64)	($10.55)
Basic Weighted Average Shares Outstanding (in shares)	9,449,189	4,665,316	1,342,174
Diluted Weighted Average Shares Outstanding (in shares)	9,461,663	4,675,974	1,346,161

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Stockholders' Equity (Deficit) (USD $)	Total	Preferred Stock	Preferred Stock	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Deficit	Gentris Corporation	Gentris Corporation	Gentris Corporation	BioServe	BioServe	BioServe	Non-Employee	Non-Employee	Employee	Employee	Employee
		Series A Preferred Stock	Series B Preferred Stock						Common Stock	Additional Paid-in Capital		Common Stock	Additional Paid-in Capital		Additional Paid-in Capital		Common Stock	Additional Paid-in Capital
Balance at Dec. 31, 2011	($19,065,357)	$59	$182	$130	$23,220,672	($17,442)	($42,268,958)
Balance (in shares) at Dec. 31, 2011		587,691	1,821,600	1,295,026
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock based compensation issued during period														573,365	573,365	341,996		341,996
Warrant extension	144,000				144,000
Exercise of warrants (in shares)				54,910
Exercise of warrants	690,227			5	690,222
Net loss	-6,665,627						-6,665,627
Balance at Dec. 31, 2012	-23,981,396	59	182	135	24,970,255	-17,442	-48,934,585
Balance (in shares) at Dec. 31, 2012		587,691	1,821,600	1,349,936
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock based compensation issued during period														88,162	88,162	646,983		646,983
Exercise of warrants (in shares)				78,329
Exercise of warrants	612,000			8	611,992
Stock based compensation-employees (in shares)																	2,500
Vesting of common pursuant to joint venture agreement	231,396				231,396
Conversion of preferred stock into common stock (in shares)		-587,691	-1,821,600	1,287,325
Conversion of preferred stock into common stock		-59	-182	129	112
Conversion of debt into common stock (in shares)				963,430
Conversion of debt into common stock	12,596,066			96	12,595,970
Issuance of common stock in IPO, net of offering costs (in shares)				690,000
Issuance of common stock in IPO, net of offering costs	3,742,643			69	3,742,574
Issuance of common stock (in shares)				1,605,000
Issuance of common stock	14,230,372			160	14,230,212
Issuance of common stock in Follow-On Offering, net of offering costs (in shares)				3,286,700
Issuance of common stock in Follow-On Offering, net of offering costs	42,302,596			329	42,302,267
Issuance of common stock pursuant to license agreement (in shares)				2,000
Issuance of common stock pursuant to license agreement	20,000				20,000
Issuance of common stock pursuant to Joint venture agreement (in shares)				10,000
Issuance of common stock pursuant to joint venture agreement	175,300			1	175,299
Reclassification of derivative warrants	7,170,000				7,170,000
Exercise of options (in shares)	164			164
Exercise of options	1,640				1,640
Retirement of treasury stock						17,442	-17,442
Net loss	-12,372,553						-12,372,553
Balance at Dec. 31, 2013	45,463,209	0	0	927	106,786,862	0	-61,324,580
Balance (in shares) at Dec. 31, 2013		0	0	9,275,384
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock based compensation issued during period														373,374	373,374	3,461,975	21	3,461,954
Exercise of warrants (in shares)				135,323
Exercise of warrants	303,102			14	303,088
Stock based compensation-employees (in shares)														5,000			207,500
Conversion of preferred stock into common stock	0
Exercise of options (in shares)	30,083			18,749
Exercise of options	79,018			2	79,016
Retirement of treasury stock	0
Equity interest number of shares									147,843			31,370
Value of shares issued as partial consideration to purchase Gentris and BioServe								1,271,745	15	1,271,730	244,247	3	244,244
Net loss	-16,642,919						-16,642,919
Balance at Dec. 31, 2014	$34,553,751	$0	$0	$982	$112,520,268	$0	($77,967,499)
Balance (in shares) at Dec. 31, 2014		0	0	9,821,169

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	($16,642,919)	($12,372,553)	($6,665,627)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	810,158	311,247	338,176
Amortization	28,438	15,229	15,229
Provision (recovery) for bad debts	215,176	0	-4,597
Equity-based consulting and compensation expenses	3,835,349	646,983	915,361
Equity-based research and development/general and administrative expenses	0	514,858	0
Change in fair value of warrant liability	-417,000	-4,633,000	-7,538,000
Change in fair value of acquisition note payable	-198,000	0	0
Extension of warrants	0	0	144,000
Amortization of loan guarantee and financing fees	310,500	1,194,960	1,427,296
Accretion of discount on debt	0	584,692	2,212,154
Deferred rent	-37,645	6,491	7,987
Loss in equity-method investment	939,913	12,343	0
Loss on debt and warrant restructuring	0	0	1,862,012
Loss on conversion of debt to equity	0	6,849,830	0
Deferred initial public offering costs expensed	0	617,706	0
Change in working capital components:
Accounts receivable	-1,656,658	-716,494	-156,968
Other current assets	-198,658	-375,338	-220,009
Accounts payable, accrued expenses and deferred revenue	673,687	-731,471	85,134
Net cash (used in) operating activities	-12,337,659	-8,074,517	-7,577,852
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of fixed assets	-1,374,294	-257,261	-162,463
(Increase) decrease in restricted cash	-6,000,000	-50,000	-50,000
Patent costs	-129,496	-92,174	-135,306
Investment in joint venture	-1,000,000	-1,000,000	0
Net cash (used in) investing activities	-11,372,733	-1,399,435	-347,769
CASH FLOWS FROM FINANCING ACTIVITIES
Principal payments on capital lease obligations	-43,842	-17,158	-36,120
Proceeds from public offerings of common stock, net of offering costs	0	61,516,994	0
Payment of equity issuance costs	0	0	-1,373,000
Proceeds from warrant exercises	178,102	192,000	635,227
Proceeds from option exercises	79,018	1,640	0
Principal payments on notes payable	-408,386	-3,579,866	-17,836
Proceeds from borrowings on notes payable	0	0	7,120,000
Payments on line of credit	0	0	0
Proceeds from borrowings on line of credit	0	0	0
Net cash (used in) financing activities	-195,108	58,113,610	6,328,271
Net (decrease) increase in cash and cash equivalents	-23,905,500	48,639,658	-1,597,350
CASH AND CASH EQUIVALENTS
Beginning	49,459,564	819,906
Ending	25,554,064	49,459,564	819,906
SUPPLEMENTAL CASH FLOW DISCLOSURE
Cash paid for interest	128,417	608,084	1,091,377
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES
Fixed assets acquired through capital lease arrangement	42,000	353,687	0
Warrants issued with debt	0	0	6,122,000
Warrants issued for debt guarantee fee	0	0	1,583,000
Warrants issued for financing fees	0	47,000	1,003,000
Retirement of treasury stock	0	17,442	0
Conversion of notes payable and lines of credit to common stock	0	9,634,300	0
Value of shares issued as partial consideration to purchase Gentris and BioServe	1,515,992	0	0
Conversion of preferred stock to common stock	0	241	0
Reclassification of derivative warrants	0	7,170,000	0
Cashless exercise of derivative warrants	125,000	420,000	0
Offering costs discounted	0	733,250	0
Net tangible assets acquired via acquisition	1,255,084	0	0
Accrued IPO costs	0	0	1,732,016
Accrued expenses recorded as financing fees	0	0	251,000
Accrued expenses reclassified as derivative warrant liability	0	221,000	148,000
Derivative warrant settled with accrued expense	0	0	182,500
Gentris Corporation
CASH FLOWS FROM INVESTING ACTIVITIES
Cash used in acquisition of Gentris, net of cash received	-3,180,930	0	0
BioServe
CASH FLOWS FROM INVESTING ACTIVITIES
Cash from acquisition of BioServe	$311,987	$0	$0

Organization_Acquisitions_Desc

Organization, Acquisitions, Description of Business, Reverse Stock Split and Charter Amendment	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Acquisitions, Description of Business, Reverse Stock Split and Charter Amendment	Organization, Acquisitions, Description of Business, Reverse Stock Split and Charter Amendment
	We are an oncology diagnostics company focused on developing, commercializing and providing DNA-based tests and services to improve the personalization of cancer treatment and to better inform biopharmaceutical companies of genomic factors influencing subject responses to therapeutics. Our vision is to become the oncology diagnostics partner for companies and clinicians by participating in the entire care continuum from bench to bedside. We believe the diagnostic industry is undergoing a metamorphosis in its approach to oncology testing, embracing individualized medicine as a means to drive higher standards of patient treatment and disease management. Similarly, biopharma companies are increasingly engaging companies such as ours to provide information on clinical trial participants’ DNA profiles in order to identify genomic variations that may be responsible for differing responses to pharmaceuticals, and particularly to oncology drugs, thereby increasing the efficiency of trials while lowering related costs. We believe tailored therapeutics can revolutionize oncology medicine through DNA-based testing services, enabling physicians and researchers to target the factors that make each patient and disease unique. We have created a unique position in the industry by providing targeted somatic analysis of tumor sample cells alongside germline analysis of an individuals' non-cancerous cells' DNA as we attempt to reach the next milestone in personalized medicine. Individuals are born with germline mutations and somatic mutations arise in tissues over the course of a lifetime.
	We were incorporated in the State of Delaware on April 8, 1999 and have offices and state-of-the-art laboratories located in New Jersey, North Carolina, Shanghai (China), and Hyderabad, India. Our laboratories comply with the highest regulatory standards as appropriate for the services they deliver including CLIA, CAP, NY State and NABL (India). We have two advisory boards to counsel our scientific and clinical direction. Our Scientific Advisory Board is comprised of preeminent scientists and physicians from the fields of cancer biology, cancer pathology, cancer medicine and molecular genetics.  Our Clinical Advisory Board is comprised of clinicians and scientists focused on clinical implementation of our proprietary tests and services and mapping those tests and services to patient needs.  Our services are built on a foundation of world-class scientific knowledge and intellectual property in solid and blood-borne cancers, as well as strong academic relationships with major cancer centers such as Memorial Sloan-Kettering, Mayo Clinic, and the National Cancer Institute.
	Acquisition of Gentris Corporation
	On July 16, 2014, we purchased substantially all of the assets of Gentris Corporation ("Gentris"), a laboratory specializing in pharmacogenomics profiling for therapeutic development, companion diagnostics and clinical trials. Gentris’ laboratory is located in Morrisville, North Carolina and the company has a CLIA and FDA-compliant laboratory facility in Shanghai, China. Upon closing of the acquisition transaction, Gentris Corporation was re-named Gentris, LLC and is now a wholly-owned subsidiary of Cancer Genetics, Inc. The acquisition allows us to expand our biopharma services.
	The assets and liabilities of Gentris were recorded in our consolidated financial statements at their estimated fair values as of the acquisition date. The excess value of the consideration paid over the fair value of assets acquired and liabilities assumed was recorded as goodwill. Goodwill arising from the acquisition consists largely from a trained workforce in place and expected synergies with existing operations. Goodwill recorded in conjunction with the acquisition is deductible for income tax purposes. The total consideration for the Gentris acquisition is as follows:
		Amount
	Cash paid at closing	$	3,250,000
	Issuance of 147,843 common shares	1,271,745
	Estimated fair value of contingent consideration	293,400
	Total Purchase Price	$	4,815,145
	The estimated fair value of contingent consideration is a potential earn-out which is payable in cash or shares of our common stock at our option, and is based upon a formula that provides for additional amounts, for revenues starting at $4.75 million, up to revenues of $8.55 million, plus a potential payment to be made in connection with the termination of a biorepository relationship with Gentris, based upon exit fees to be received by Gentris. The amounts used in computing the purchase price differ from the amounts in the purchase agreements due to fair value measurement conventions prescribed in accounting standards.
	We incurred a finder's fee of $147,500 related to the transaction.
	The transaction is being accounted for using the acquisition method of accounting for business combinations in accordance with GAAP. Under this method, the total consideration transferred to consummate the acquisition is being allocated to the identifiable tangible and intangible assets acquired and liabilities assumed based on their respective fair values as of the closing date of the acquisition. The acquisition method of accounting requires extensive use of estimates and judgments to allocate the consideration transferred to the identifiable tangible and intangible assets acquired and liabilities assumed. Accordingly, the allocation of the consideration transferred in the consolidated financial statements is preliminary and will be adjusted upon completion of the final valuation of the assets acquired and liabilities assumed. The final valuation of fixed assets, intangibles and deferred revenue is expected to be completed as soon as practicable but no later than twelve months after the closing date of the acquisition.
	The preliminary allocation of the total purchase price to the fair value of the assets acquired and liabilities assumed as of July 16, 2014 are as follows:
		Amount
	Accounts receivable	$	1,869,097
	Other current assets	265,612
	Current liabilities	(785,246		)
	Deferred revenue, long-term	(937,773		)
	Fixed Assets	1,950,885
	Goodwill	2,452,570
	Total Purchase Price	$	4,815,145
	Acquisition of BioServe Biotechnologies (India) Pvt. Ltd.
	On August 18, 2014 we entered into two agreements by which we acquired BioServe Biotechnologies (India) Pvt. Ltd., a premier genomics services provider serving both the research and clinical markets in India. This transaction was completed through a newly formed subsidiary, Cancer Genetics (India) Pvt. Ltd.
	BioServe is a leading genomic service and next-generation sequencing company serving both the research and clinical markets based in Hyderabad, India. With the BioServe acquisition we believe we will be able to access the Indian healthcare market. The acquisition provides us with an infrastructure in India for developing lower cost manufacturing of probes and kits including probes and kits used for our proprietary FHACT test and access to one of the fastest-growing molecular and clinical diagnostic markets in the world. BioServe will continue to serve biotechnology and biopharmaceutical companies, diagnostic companies and research hospitals, including those owned or operated by the Indian government, as well as seek to expand its customer base.
	The parties to the first agreement (the “India Agreement”) are the Company, Ramakishna V. Modali (the current general manager of BioServe, “Modali”), VenturEast Trustee Company Pvt Ltd and affiliates, its principal shareholder (“VenturEast”), and certain other shareholders residing in India all of whom in the aggregate owned approximately 74% of BioServe. The parties to the second share purchase agreement (the “US Agreement”) are the Company and BioServe Biotechnologies LTD, a Maryland corporation and an affiliate of BioServe which owned approximately 15% of BioServe, with the other outstanding shares held by the BioServe Employee Stock Ownership Plan which will remain in place.
	The assets and liabilities of BioServe were recorded in the Company's consolidated financial statements at their estimated fair values as of the acquisition date. The excess value of the consideration paid over the fair value of assets acquired and liabilities assumed is recorded as goodwill. Goodwill arising from the acquisition consists largely from a trained workforce in place and expected synergies from new lines of business. Goodwill recorded in conjunction with the acquisition is not deductible for income tax purposes. The aggregate purchase price is as follows:
		Amount
	Cash paid at closing	$	72,907
	Notes payable due 12-18 months after closing	23,708
	Notes payable (value of 84,278 common shares)	733,387
	Issuance of 31,370 common shares	244,247
	Total Purchase Price	$	1,074,249
	The ultimate payment to VenturEast will be a cash payment equal to the value of 84,278 shares of our common stock at the time of payment. This payment will be made the earlier of 30 months from the date of the acquisition agreement (November 2016) or the date of a public offering by us of our common stock. This liability is subject to future adjustment based upon changes to our stock price. During the year ended December 31, 2014, we recognized a gain of $198,000 due to the decrease in value of this note. The amounts used in computing the purchase price differ from the amounts in the purchase agreements due to fair value measurement conventions prescribed in accounting standards.
	The transaction is being accounted for using the acquisition method of accounting for business combinations in accordance with GAAP. Under this method, the total consideration transferred to consummate the acquisition is being allocated to the identifiable tangible and intangible assets acquired and liabilities assumed based on their respective fair values as of the closing date of the acquisition. The acquisition method of accounting requires extensive use of estimates and judgments to allocate the consideration transferred to the identifiable tangible and intangible assets acquired and liabilities assumed. Accordingly, the allocation of the consideration transferred in the consolidated financial statements is preliminary and will be adjusted upon completion of the final valuation of the assets acquired and liabilities assumed. The final valuation of fixed assets and intangibles is expected to be completed as soon as practicable but no later than twelve months after the closing date of the acquisition.
	The preliminary allocation of the total purchase price to the fair value of the assets acquired and liabilities assumed as of August 18, 2014 are as follows:
		Amount
	Accounts receivable	$	151,002
	Other current assets	120,528
	Fixed Assets	624,948
	Other assets	416,869
	Goodwill	541,565
	Current liabilities	(758,614		)
	Other liabilities	(22,049		)
	Total Purchase Price	$	1,074,249
	The following table provides certain proforma financial information for the Company as if the acquisitions discussed above occurred on January 1, 2012:
		Unaudited
		Year Ended December 31,
		2014			2013			2012
	Revenue	$	14,365,402		$	15,767,519		$	12,528,553
	Net loss	(18,498,333		)	(13,677,432		)	(7,918,262		)
	Basic net loss per share	$	(1.94	)	$	(2.82	)	$	(5.20	)
	Dilutive net loss per share	(1.98		)	(3.77		)	(10.13		)
	The results of operations for the twelve months ended December 31, 2014 include the operations of Gentris from July 16, 2014 and BioServe from August 18, 2014 and include combined revenues of $3,296,465 and a combined net loss of $1,438,118.
	Reverse Stock Splits
	On February 8, 2013, we filed a charter amendment with the Secretary of State for the State of Delaware and effected a 1-for-2 reverse stock split of our common stock. On March 1, 2013, we filed another charter amendment with the Secretary of State for the State of Delaware and effected a 1-for-2.5 reverse stock split of our common stock. All shares and per share information referenced throughout the consolidated financial statements have been retroactively adjusted to reflect both reverse stock splits.
	Public Offerings
	On April 10, 2013, we sold 690,000 shares of common stock at a public offering price of $10.00 per share and completed our initial public offering (“IPO”) with gross proceeds of $6.9 million (net proceeds of $5 million). Upon the closing of the IPO, all shares of our then-outstanding Series A and Series B convertible preferred stock automatically converted into an aggregate of 1,287,325 shares of common stock. Concurrent with the IPO, certain derivative warrants with a fair value of $7.2 million were reclassified into equity due to the lapsing of anti-dilution provisions in the warrants. Also concurrent with the IPO, $9.6 million of debt converted into 963,430 shares of common stock. All references to our Series A convertible preferred stock refer collectively to the Series A and Series A-1 convertible preferred shares.
	On August 19, 2013, we sold 1,500,000 shares of common stock at a public offering price of $10.00 per share resulting in gross proceeds of $15.0 million (net proceeds of $13.3 million). We used $3.5 million of the proceeds to repay certain indebtedness which was due on August 15, 2013 (see Note 6 for further discussion of the Company’s debt). On September 5, 2013, we sold 105,000 additional common shares pursuant to partial exercise of the underwriter’s over-allotment option which resulted in gross proceeds of $1.1 million (net proceeds of $947,000). All references to the sales of common stock mentioned in this paragraph are referred to as the “Secondary Offering.”
	On October 28, 2013, we sold 3,286,700 shares of common stock, (including the underwriter’s overallotment of 428,700 shares), at a public offering price of $14.00 per share resulting in gross proceeds of $46.0 million (net proceeds of $42.3 million). All references to the sales of common stock mentioned in this paragraph are referred to as the “Follow-On Offering.”

Significant_Accounting_Policie

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies	Significant Accounting Policies
	Basis of presentation: We prepare our financial statements on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.
	Segment Reporting: Operating segments are defined as components of an enterprise about which separate discrete information is used by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. We view our operations and manage our business in one operating segment, which is the business of developing and selling diagnostic tests.
	Liquidity: Our primary sources of liquidity have been funds generated from our debt financings and equity financings. In addition, we have generated funds from the following sources: (i) cash collections from our customers; (ii) grants from the National Institutes of Health and (iii) the sale of State of New Jersey net operating loss carryforwards.
	Principles of consolidation: The accompanying consolidated financial statements include the accounts of Cancer Genetics, Inc. and our wholly owned subsidiaries, Cancer Genetics Italia S.r.l (“CGI Italia”), Gentris LLC (from July 16, 2014) and CGI India (BioServe) (from August 18, 2014).
	All significant intercompany account balances and transactions have been eliminated in consolidation.
	Use of estimates and assumptions: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates made by management include, among others, realization of amounts billed, realization of long-lived assets, realization of intangible assets, accruals for litigation and registration payments, assumptions used to value stock options, warrants and goodwill and the valuation of assets acquired and liabilities assumed from acquisitions. Actual results could differ from those estimates.
	Risks and uncertainties: We operate in an industry that is subject to intense competition, government regulation and rapid technological change. Our operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory, foreign operations, and other risks, including the potential risk of business failure.
	Cash and cash equivalents: Highly liquid investments with original maturities of three months or less when purchased are considered to be cash equivalents. Financial instruments which potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents. We maintain cash and cash equivalents with high-credit quality financial institutions. At times, such amounts may exceed insured limits. We have not experienced any losses in such accounts and believe we are not exposed to any significant credit risk on our cash and cash equivalents.
	Restricted cash: Represents cash held at financial institutions which we may not withdraw and which collateralizes certain of our financial commitments. All of our restricted cash is invested in interest bearing certificates of deposit. Our restricted cash collateralizes a fully-utilized $6.0 million line of credit with Wells Fargo Bank and a $300,000 letter of credit in favor of our landlord, pursuant to the terms of the lease for our Rutherford facility.
	Revenue recognition: Revenue is recognized in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605, Revenue Recognition, and ASC 954-605 Health Care Entities, Revenue Recognition which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the customer or services have been rendered; (3)the price is fixed or determinable; and (4) collectability is reasonably assured. In determining whether the price is fixed or determinable, we consider payment limits imposed by insurance carriers and Medicare and the amount of revenue recorded takes into account the historical percentage of revenue we have collected for each type of test for each payor category. Periodically, an adjustment is made to revenue to record differences between our anticipated cash receipts from insurance carriers and Medicare and actual receipts from such payors. For the periods presented, such adjustments were not significant. For some Clinical Service and Biopharma customers billed directly, revenue is recorded based upon the contractually agreed upon fee schedule. When assessing collectability, we consider whether we have sufficient payment history to reliably estimate a payor’s individual payment patterns. For new tests where there is no evidence of payment history at the time the tests are completed, we only recognize revenues once reimbursement experience can be established. We then recognize revenue equal to the amount of cash received. We do not bill customers for shipping and handling fees and do not collect any sales or other taxes.
	Revenues from grants to support product development are recognized when costs and expenses under the terms of the grant have been incurred and payments under the grants become contractually due.
	Accounts receivable: Accounts receivable are carried at original invoice amount less an estimate for contractual adjustments and doubtful receivables, the amounts of which are determined by an analysis of individual accounts. Our policy for assessing the collectability of receivables is dependent upon the major payor source of the underlying revenue. For direct bill clients, an assessment of credit worthiness is performed prior to initial engagement and is reassessed periodically. If deemed necessary, an allowance is established on receivables from direct bill clients. For insurance carriers where there is not an established pattern of collection, revenue is not recorded until cash is received. For receivables where insurance carriers have made payments to patients instead of directing payments to the Company, an allowance is established for a portion of such receivables. After reasonable collection efforts are exhausted, amounts deemed to be uncollectible are written off against the allowance for doubtful accounts. Since the Company only recognizes revenue to the extent it expects to collect such amounts, bad debt expense related to receivables from patient service revenue is recorded in general and administrative expense in the consolidated statement of operations. Recoveries of accounts receivable previously written off are recorded when received.
	Deferred revenue: Payments received in advance of services rendered are recorded as deferred revenue and are subsequently recognized as revenue in the period in which the services are performed.
	Fixed assets: Fixed assets consist of diagnostic equipment, furniture and fixtures and leasehold improvements. Fixed assets are carried at cost and are depreciated using the straight-line method over the estimated useful lives of the assets, which generally range from five to seven years. Leasehold improvements are depreciated over the lesser of the lease term or the estimated useful lives of the improvements using the straight-line method. Repairs and maintenance are charged to expense as incurred while improvements are capitalized. Upon sale, retirement or disposal of fixed assets, the accounts are relieved of the cost and the related accumulated depreciation with any gain or loss recorded to the consolidated statement of operations.
	Fixed assets are reviewed for impairment whenever changes in circumstances indicate that the carrying amount of an asset may not be recoverable. These computations utilize judgments and assumptions inherent in our estimate of future cash flows to determine recoverability of these assets. If our assumptions about these assets were to change as a result of events or circumstances, we may be required to record an impairment loss.
	Goodwill: Goodwill resulted from the purchases of Gentris and BioServe in 2014 as described in Note 1. In accordance with ASC 350, Intangibles - Goodwill and Other, we are required to test goodwill for impairment and adjust for impairment losses, if any, at least annually and on an interim basis if an event or circumstance indicates that it is likely impairment has occurred. Our annual goodwill impairment testing date is October 1 of each year. No such losses were incurred during the year ended December 31, 2014.
	Goodwill
	Balance, December 31, 2013	$	—
	Purchased through acquisitions	2,994,135
	Balance, December 31, 2014	$	2,994,135
	Loan guarantee and financing fees: Loan guarantee fees are amortized on a straight-line basis over the term of the guarantee. Financing fees are amortized using the effective interest method over the term of the related debt.
	Warrant liability: We have issued certain warrants which contain an exercise price adjustment feature in the event we issue additional equity instruments at a price lower than the exercise price of the warrant. The warrants are described herein as derivative warrants. We account for these derivative warrants as liabilities. These common stock purchase warrants do not trade in an active securities market, and as such, we estimate the fair value of these warrants using the binomial lattice valuation pricing model with the assumptions as follows: The risk-free interest rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve. The expected life of the warrants is based upon the contractual life of the warrants. Volatility is estimated based on an average of the historical volatilities of the common stock of four entities with characteristics similar to those of the Company. Prior to our IPO, the measurement date fair value of the underlying common shares was based upon an external valuation of our shares. (See Notes 12 and 13). Subsequent to the IPO and Secondary Offering, we used the closing price of our shares on the OTC Bulletin Board and the NASDAQ Capital Market, respectively.
	We compute the fair value of the warrant liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the warrant liability is our stock price, which is subject to significant fluctuation and is not under our control. The resulting effect on our net income (loss) is therefore subject to significant fluctuation and will continue to be so until the warrants are exercised, amended or expire. Assuming all other fair value inputs remain constant, we will record non-cash expense when the stock price increases and non-cash income when the stock price decreases.
	Income taxes: Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due plus deferred income taxes. Deferred income taxes are recognized for temporary differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future. Deferred income taxes are also recognized for net operating loss carryforwards that are available to offset future taxable income and research and development credits.
	Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. We have established a full valuation allowance on our deferred tax assets as of December 31, 2014 and 2013, therefore we have not recognized any tax benefit or expense in the periods presented.
	ASC 740, Income Taxes, clarifies the accounting for uncertainty in income taxes recognized in the financial statements. ASC 740 provides that a tax benefit from uncertain tax positions may be recognized when it is more-likely-than-not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. ASC 740 also provides guidance on measurement, de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. At December 31, 2014 and 2013 we had no uncertain tax positions.
	Our policy is to recognize interest and/or penalties related to income tax matters in income tax expense. There is no accrual for interest or penalties on our consolidated balance sheets at December 31, 2014 or 2013, and we have not recognized interest and/or penalties in the consolidated statements of operations for the years ended December 31, 2014, 2013 or 2012.
	Patents: We account for intangible assets under ASC 350-30. Patents consist of legal fees incurred and are recorded at cost and amortized over the useful lives of the assets, using the straight-line method. Certain patents are in the legal application process and therefore are not currently being amortized. We review the carrying value of patents at the end of each reporting period. Based upon our review, there were no intangible asset impairments in 2014, 2013 or 2012. Accumulated amortization of patents as of December 31, 2014 and 2013 was approximately $84,000 and $56,000, respectively. Future amortization expense for legally approved patents (excluding patent applications in progress), is estimated at $34,900 per year through 2018, approximately $31,600 for 2019 and $93,400 thereafter.
	Research and development: Research and development costs associated with service and product development include direct costs of payroll, employee benefits, stock-based compensation and supplies and an allocation of indirect costs including rent, utilities, depreciation and repairs and maintenance. All research and development costs are expensed as they are incurred.
	Registration payment arrangements: We account for our obligations under registration payment arrangements in accordance with ASC 825-20, Registration Payment Arrangements. ASC 825-20 requires us to record a liability if we determine a registration payment is probable and if it can reasonably be estimated. As of both December 31, 2014 and 2013, we have an accrued liability of $300,000.
	Stock-based compensation: Stock-based compensation is accounted for in accordance with the provisions of ASC 718, Compensation-Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. We estimate the fair value of stock-based awards on the date of grant using the Black-Scholes option pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. See additional information in Note 11.
	All issuances of stock options or other issuances of equity instruments to employees as the consideration for services received by us are accounted for based on the fair value of the equity instrument issued.
	We account for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity Based Payments to Non-Employees. Under ASC 505-50, we determine the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Stock-based compensation awards issued to non-employees are recorded in expense and additional paid-in capital in stockholders’ equity (deficit) over the applicable service periods based on the fair value of the awards or consideration received at the vesting date.
	Fair value of financial instruments: The carrying amount of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses, approximate their estimated fair values due to the short term maturities of those financial instruments. These financial instruments are considered Level 1 measurements under the fair value hierarchy. The fair values of our notes payable, lines of credit and capital leases approximate carrying value under Level 2 of the fair value hierarchy. The fair value of warrants recorded as derivative liabilities, contingent consideration and note payable to VenturEast are described in Note 14.
	Joint venture accounted for under the equity method: The Company records its joint venture investment following the equity method of accounting, reflecting its initial investment in the joint venture and its share of the joint venture’s net earnings or losses and distributions. The Company’s share of the joint venture’s net loss was approximately $940,000 in 2014 and $12,000 in 2013 (the first year of the joint venture’s operations) and is included in Research and development expense on the Consolidated Statement of Operations. The Company has a net receivable due from the joint venture of approximately $10,000 and $24,000 in 2014 and 2013, respectively, which is included in other assets in the Consolidated Balance Sheet. See additional information in Note 16.
	Subsequent events: We have evaluated potential subsequent events through the date the financial statements were issued.
	Recent Accounting Pronouncements: In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), requiring an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The updated standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either a full retrospective or retrospective with cumulative effect transition method. Early adoption is not permitted. The updated standard becomes effective for the Company in the first quarter of fiscal year 2017.  The Company has not yet selected a transition method and is currently evaluating the effect that the updated standard will have on the consolidated financial statements.
	Earnings (loss) per share: Basic earnings (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares assumed to be outstanding during the period of computation. Diluted earnings per share is computed similar to basic earnings per share except that the numerator is adjusted for the change in fair value of the warrant liability (only if dilutive) and the denominator is increased to include the number of dilutive potential common shares outstanding during the period using the treasury stock method.
	Basic net loss and diluted net loss per share data were computed as follows:
		2014			2013			2012
	Numerator:
	Net (loss) for basic earnings per share	$	(16,642,919	)	$	(12,372,553	)	$	(6,665,627	)
	Less change in fair value of warrant liability	417,000			4,633,000			7,538,000
	Net (loss) for diluted earnings per share	$	(17,059,919	)	$	(17,005,553	)	$	(14,203,627	)
	Denominator:
	Weighted-average basic common shares outstanding	9,449,189			4,665,316			1,342,174
	Assumed conversion of dilutive securities:
	Common stock purchase warrants	12,474			10,658			3,987
	Potentially dilutive common shares	12,474			10,658			3,987
	Denominator for diluted earnings per share—adjusted weighted-average shares	9,461,663			4,675,974			1,346,161
	Basic net loss per share	$	(1.76	)	$	(2.65	)	$	(4.97	)
	Diluted net loss per share	$	(1.80	)	$	(3.64	)	$	(10.55	)
	The following table summarizes potentially dilutive adjustments to the weighted average number of common shares which were excluded from the calculation:
		2014			2013			2012
	Common stock purchase warrants	$	1,060,863		$	1,701,984		$	1,102,176
	Stock options	1,839,458			873,542			553,340
	Restricted shares of common stock	132,500			7,500			—
	Common shares issuable upon conversion of Series A Preferred Stock	—			—			352,614
	Common shares issuable upon conversion of Series B Preferred Stock	—			—			364,320
		$	3,032,821		$	2,583,026		$	2,372,450

Revenue_and_Accounts_Receivabl

Revenue and Accounts Receivable	12 Months Ended
	Dec. 31, 2014
Receivables [Abstract]
Revenue and Accounts Receivable	Revenue and Accounts Receivable
	Revenue by service type for each of the years ended December 31 is comprised of the following:
		2014				2013				2012
	Biopharma Services	$	5,605,780			$	2,650,285			$	578,505
	Clinical Services	4,432,272				3,662,795				3,166,118
	Discovery Services	161,335				—				—
	Grants	—				296,877				556,940
		$	10,199,387			$	6,609,957			$	4,301,563
	Accounts receivable by service type at December 31, 2014 and 2013 consists of the following:
		2014				2013
	Biopharma Services	$	3,203,335			$	428,341
	Clinical Services	1,925,176				1,174,698
	Discovery Services	151,285				—
	Allowance for doubtful accounts	(251,176		)		(36,000		)
		$	5,028,620			$	1,567,039
	Allowance for Doubtful Accounts
	Balance, December 31, 2012	$	36,000
	Additions to Allowance for doubtful accounts	—
	Deductions to Allowance for doubtful accounts	—
	Balance, December 31, 2013	36,000
	Additions to Allowance for doubtful accounts	215,176
	Deductions to Allowance for doubtful accounts	—
	Balance, December 31, 2014	$	251,176
	Revenue for Biopharma Services are customized solutions for patient stratification and treatment selection through an extensive suite of DNA-based testing services. Clinical Services are tests performed to provide information on diagnosis, prognosis and theranosis of cancers to guide patient management. These tests can be billed to Medicare, another third party insurer or the referring community hospital or other healthcare facility. Discovery Services are services that provide the tools and testing methods for companies and researchers seeking to identify new DNA-based biomarkers for disease. Grants includes revenue from grants. The breakdown of our Clinical Services revenue (as a percent of total revenue) is as follows:
		2014			2013			2012
	Medicare	11	%		13	%		18	%
	Other insurers	16	%		25	%		32	%
	Other healthcare facilities	16	%		18	%		24	%
	Total Clinical Services	43	%		55	%		74	%
	We have historically derived a significant portion of our revenue from a limited number of test ordering sites. The test ordering sites are largely hospitals, cancer centers, reference laboratories, physician offices and clinical trial clients. Oncologists and pathologists at these sites order the tests on behalf of the needs of their oncology patients or as part of a clinical trial sponsored by a biopharmaceutical company in which the patient is being enrolled. We generally do not have formal, long-term written agreements with such test ordering sites, and, as a result, we may lose a significant test ordering site at any time.
	The top five test ordering clients during 2014, 2013 and 2012 accounted for 56%, 69% and 58% respectively, of our testing volumes, with 38%, 36% and 46% respectively, of the test volume coming from community hospitals. During the year ended December 31, 2014, two Biopharma clients accounted for approximately 23% and 12% respectively of our revenue. During the year ended December 31, 2013 there was one Biopharma client that accounted for approximately 40% of our revenue. During 2012 there were three clients, that each accounted for more than 10% of our revenue: a Biopharma client accounted for approximately 13%, a university teaching center accounted for approximately 11% and a community hospital accounted for approximately 10% of our revenue.

Other_Current_Assets

Other Current Assets	12 Months Ended
	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Current Assets	Other Current Assets
	At December 31, 2014 and 2013, other current assets consisted of the following:
		2014		2013
	Inventory	$	279,894	$	198,789
	Prepaid expenses	911,320		593,950
	Grants receivable	—		71,877
		$	1,191,214	$	864,616

Lease_Commitments

Lease Commitments	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
Lease Commitments	Lease Commitments
	We lease our laboratory, research facility and administrative office space under various operating leases. We have approximately 17,900 square feet of office and laboratory space in Rutherford, New Jersey, 24,900 square feet in Morrisville, North Carolina, 10,000 square feet in Hyderabad, India and 2,700 square feet in Shanghai, China. We have escalating lease agreements for both our New Jersey and North Carolina spaces which expire February 2018 and May 2020, respectively. These leases require monthly rent with periodic rent increases that vary from $1 to $2 per square foot of the rented premises per year. The difference between minimum rent and straight-line rent is recorded as deferred rent payable. The terms of our New Jersey lease require that a $300,000 security deposit for the facility be held in a stand by letter of credit in favor of the landlord (see Note 7).
	We acquired office and scientific equipment under long term leases which have been capitalized at the present value of the minimum lease payments. The equipment under these capital leases had a cost of $395,687 and accumulated depreciation of $29,936, as of December 31, 2014.
	Minimum future lease payments under all capital and operating leases as of December 31, 2014 are as follows:
		Capital		Operating		Total
		Leases		Leases
	December 31,
	2015	$	74,280	$	854,195	$	928,475
	2016	74,280		862,957		937,237
	2017	61,625		870,407		932,032
	2018	59,094		360,140		419,234
	2019	59,094		320,885		379,979
	Thereafter	83,800		135,075		218,875
	Total minimum lease payments	$	412,173	$	3,403,659	$	3,815,832
	Less amount representing interest	52,838
	Present value of net minimum obligations	359,335
	Less current obligation under capital lease	58,950
	Long-term obligation under capital lease	$	300,385
	Rent expense for the years ended December 31, 2014, 2013 and 2012 was $692,324, $550,882, and $516,173, respectively.

Notes_Payable_and_Lines_of_Cre

Notes Payable and Lines of Credit	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Notes Payable and Lines of Credit	Notes Payable and Lines of Credit
	Below is a summary of our short-term and long-term debt obligations as of December 31, 2014 and 2013:
			December 31,		December 31,
			2014		2013
	Secured Note Payable, short-term		$	—	$	22,298
	Notes Payable, Current Portion		$	—	$	22,298
	Line of Credit, Current Portion		$	—	$	6,000,000
	Lines of Credit, Current Portion		$	—	$	6,000,000
	Lines of Credit, Long-Term		$	6,000,000
	Lines of Credit, Long-Term		$	6,000,000	$	—
	Business Line of Credit — Wells Fargo
	At December 31, 2014 and 2013, we have fully utilized a line of credit with Wells Fargo Bank which provides for maximum borrowings of $6 million. On April 1, 2014 we entered into a credit agreement and re-negotiated the terms of our fully utilized line of credit with Wells Fargo Bank. The line of credit was extended through April 1, 2016 at a rate of interest equal to the Daily One Month LIBOR rate plus 1.75% (1.91% at December 31, 2014). The facility requires monthly interest payments.
	The line of credit is collateralized with $6 million in cash. Additionally, we are required to maintain limits on capital spending and are restricted as to the amount we may pledge as collateral for additional borrowings from any source. The line of credit requires the repayment of principal, and any unpaid interest, in a single payment due upon maturity.
	Conversion of Debt concurrent with IPO
	On April 10, 2013, we completed our IPO and converted the following indebtedness into shares of common stock at the IPO price of $10.00 per share:
			Converted Amount		Common Shares
	December 2011 Financing Transaction		$	4,500,000	450,000
	2012 Convertible Debt Financing Transaction		3,000,000		300,000
	December 2012 Bridge Financing Transaction		1,000,000		100,000
	Business Lines of Credit (DAM)		1,000,000		100,000
	Other Note Payable and accrued interest		134,300		13,430
			$	9,634,300	963,430
	In connection with the conversion of debt into common stock, we expensed the applicable remaining debt discounts of $3.5 million, financing fees of $419,000 and a contingently recognizable beneficial conversion feature in the converted debt of $3 million.
	December 2011 Financing Transaction
	The December 2011 Credit Agreement was with John Pappajohn and Andrew Pecora (indirectly through an investment company), both then members of our board of directors, and NNJCA Capital, LLC (“NNJCA”), a limited liability company of which Dr. Pecora is a member. Mr. Pappajohn originally provided $4.0 million of financing, NNJCA originally provided $1.5 million of financing and Dr. Pecora provided $500,000 of financing under the Credit Agreement. On April 10, 2013, Mr. Pappajohn converted $4.0 million and Dr. Pecora converted $500,000 into 450,000 shares of our common stock at the IPO price of $10.00 per share concurrent with our IPO. The remaining outstanding balance of $1.5 million was repaid on August 19, 2013 using a portion of the proceeds from our Secondary Offering.
	2012 Convertible Debt Financing Transaction
	On April 10, 2013, the entire $3 million outstanding under a Restated Credit Agreement dated as of August 27, 2012, as amended and restated as of October 17, 2012, ($1,750,000 provided by Mr. Pappajohn and $1,250,000 provided by Mr. Mark Oman) was converted into 300,000 shares of common stock at the IPO price of $10 per share.
	December 2012 Bridge Financing Transaction
	On April 10, 2013, the entire $1 million outstanding under a credit agreement dated as of December 7, 2012, (all of which was provided by Mr. Pappajohn), was converted into 100,000 shares of common stock at the IPO price of $10.00 per share.
	Business Line of Credit – DAM
	On April 10, 2013, $1 million of indebtedness under this line was converted into 100,000 shares of common stock at the IPO price of $10 per share. The remaining outstanding balance of $2.0 million was repaid on August 19, 2013 using a portion of the proceeds from our Secondary Offering.
	Other Note Payable
	On April 10, 2013, a $100,000 note payable and accrued interest payable to Dr. Chaganti was converted into 13,430 shares of common stock at the IPO price of $10.00 per share.
	Loss on Debt and Warrant Restructuring
	We entered into a Restated Credit Agreement with Mr. Pappajohn and Mr. Oman in October 2012 to provide for additional borrowing of $1,000,000, which agreement also removed the conversion price adjustment of a 20% discount to the IPO or merger price if the IPO or merger price is less than $53.12 per share. We evaluated the application of ASC 470-50, Modifications and Extinguishments and ASC 470-60, Troubled Debt Restructurings by Debtors and concluded that the revised terms constituted a debt extinguishment, rather than a debt modification or troubled debt restructuring.
	We cancelled certain warrants with an exercise price adjustment of a 20% discount to the IPO or merger price if the IPO or merger price is less than $53.13 per share and issued warrants without an exercise price adjustment to a 20% discount to the IPO or merger price if the IPO or merger price is less than $53.13 per share as compensation. In connection with these transactions, we recognized a loss on debt and warrant restructuring during 2012 as presented below:
	Restated 2012 convertible debt financing transaction	$	1,506,512
	Amend warrants granted for guarantee of business line of credit	268,000
	Amend warrants granted for 2011 convertible debt financing transaction	545,000
	Settle warrants granted for guarantee of business line of credit	(129,500		)
	Settle warrants granted for 2011 convertible debt financing transaction	(328,000		)
	Loss on debt and warrant restructuring - 2012	$	1,862,012

Letter_of_Credit

Letter of Credit	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Letter of Credit	Letter of Credit
	We maintain a $300,000 letter of credit in favor of our landlord pursuant to the terms of the lease for our Rutherford facility. At December 31, 2014 the letter of credit was fully secured by the restricted cash disclosed on our Consolidated Balance Sheet.

Fixed_Assets

Fixed Assets	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Fixed Assets	Fixed Assets
	Fixed assets are summarized by major classifications as follows:
		2014			2013
	Equipment	$	5,913,928		$	2,513,066
	Furniture and fixtures	548,093			461,119
	Leasehold improvements	869,578			595,689
		7,331,599			3,569,874
	Less accumulated depreciation	(2,885,006		)	(2,305,250		)
	Net fixed assets	$	4,446,593		$	1,264,624

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	The provision for income taxes for the years ended December 31, 2014, 2013 and 2012 differs from the approximate amount of income tax benefit determined by applying the U.S. federal income tax rate to pre-tax loss, due to the following:
		For the Year Ended December 31, 2014						For the Year Ended December 31, 2013					For the Year Ended December 31, 2012
		Amount			% of			Amount			% of		Amount			% of
					Pretax						Pretax					Pretax
					Loss						Loss					Loss
	Income tax benefit at federal statutory rate	$	(6,648,000	)	35	%		$	(4,563,000	)	35	%	$	(2,333,000	)	35	%
	State tax provision, net of federal tax benefit	(807,000		)	4.2	%		(359,000		)	2.8	%	(661,000		)	9.5	%
	Tax credits	(154,000		)	0.8	%		(126,000		)	1	%	(82,000		)	1.1	%
	Stock based compensation permanent differences	207,000			-1.1	%		229,000			-1.8	%	85,000			-1.2	%
	Derivative warrant permanent differences	(146,000		)	0.8	%		(1,622,000		)	12.4	%	(1,926,000		)	26	%
	Investor consideration permanent differences	(69,000		)	0.4	%		—			—	%	—			—	%
	Debt and warrant conversion costs permanent difference	—			—	%		3,454,000			-26.5	%	—			—	%
	Change in valuation allowance	5,255,000			-27.7	%		2,356,000			-18.1	%	4,858,000			-70.2	%
	Other	12,000			—	%		(33,000		)	0.3	%	59,000			-0.2	%
	Income tax (benefit) provision	$	(2,350,000	)	12.4	%		$	(664,000	)	5.1	%	$	—		—	%
	During January and December 2014, we sold $28,640,223 of gross State of New Jersey NOL carryforwards relating to tax years 2009 through 2012, resulting in the receipt of $2,350,185. During 2013, we sold $8,018,107 of gross State of New Jersey NOL carryforwards, resulting in the receipt of $663,900.
	We transferred the NOL carryforwards through the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority.
	Approximate deferred taxes consist of the following components as of December 31, 2014 and 2013:
		2014			2013
	Deferred tax assets:
	Net operating loss carryforwards	$	20,982,000		$	17,140,000
	Accruals and reserves	773,000			509,000
	Non-qualified stock options	1,912,000			877,000
	Research and development tax credits	758,000			603,000
	Derivative warrant liability	26,000			26,000
	Investment in joint venture	163,000			163,000
	Goodwill	23,000			—
	Other	6,000			5,000
	Total deferred tax assets	24,643,000			19,323,000
	Less valuation allowance	(24,558,000		)	(19,303,000		)
	Net deferred tax assets	85,000			20,000
	Deferred tax liabilities:
	Fixed assets	(85,000		)	(20,000		)
	Net deferred taxes	$	—		$	—
	Due to a history of losses we have generated since inception, we believe it is more-likely-than-not that all of the deferred tax assets will not be realized as of December 31, 2014 and 2013. Therefore, we have recorded a full valuation allowance on our deferred tax assets. We have net operating loss carryforwards for federal income tax purposes of approximately $57,000,000 as of December 31, 2014. The net operating loss carryforwards will begin to expire in 2027. Utilization of these carryforwards is subject to limitation due to ownership changes that may delay the utilization of a portion of the carryforwards.

Capital_Stock

Capital Stock	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Capital Stock	Capital Stock
	IPO
	On April 10, 2013, we completed our IPO in which we issued and sold 690,000 shares of common stock (including the underwriter’s overallotment of 90,000 shares) at a public offering price of $10.00 per share resulting in gross proceeds of $6.9 million. In connection with the offering, all outstanding shares of Series A preferred stock were converted into 376,525 shares of common stock, and all outstanding shares of Series B preferred stock were converted into 910,800 shares of common stock. Concurrent with the IPO, we issued 2,000 shares of common stock to Cleveland Clinic pursuant to our license agreement with Cleveland Clinic.
	Secondary Offering
	On August 19, 2013, we sold 1,500,000 shares of common stock at a public offering price of $10.00 per share resulting in gross proceeds of $15.0 million ($13.3 million of net proceeds after offering expenses and underwriting discounts).
	On September 5, 2013, we sold 105,000 additional common shares pursuant to the underwriter’s partial exercise of the over-allotment option which resulted in gross proceeds of $1.1 million ($947,000 of net proceeds after offering expenses and underwriting discounts).
	Follow-On Offering
	On October 28, 2013, we sold 3,286,700 shares of common stock, (including the underwriter’s overallotment of 428,700 shares), at a public offering price of $14.00 per share resulting in gross proceeds of $46.0 million (net proceeds of $42.3 million).
	Preferred Stock
	We are currently authorized to issue up to 9,764,000 shares of preferred stock.

Stock_Option_Plans

Stock Option Plans	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Option Plans	Stock Option Plans
	We have two equity incentive plans: the 2008 Stock Option Plan (the “2008 Plan”) and the 2011 Equity Incentive Plan (the “2011 Plan”, and together with the 2008 Plan, the “Stock Option Plans”). The Stock Option Plans are meant to provide additional incentive to officers, employees and consultants to remain in our employment. Options granted are generally exercisable for up to 10 years.
	The Board of Directors adopted the 2011 Plan on June 30, 2011 and reserved 350,000 shares of common stock for issuance under the 2011 Plan. On May 22, 2014, the stockholders voted to increase the number of shares reserved by the plan to 2,000,000 shares of common stock under several types of equity awards including stock options, stock appreciation rights, restricted stock awards and other awards defined in the 2011 Plan.
	The Board of Directors adopted the 2008 Plan on April 29, 2008 and reserved 251,475 shares of common stock for issuance under the plan. On April 1, 2010, the stockholders voted to increase the number of shares reserved by the plan to 550,000. We are authorized to issue incentive stock options or non-statutory stock options to eligible participants.
	We have also issued 48,000 options outside of the Stock Option Plans.
	At December 31, 2014, 386,044 shares remain available for future awards under the 2011 Plan and 89,051 shares remain available for future awards under the 2008 Plan.
	As of December 31, 2014, no stock appreciation rights and 227,500 shares of restricted stock had been awarded under the Stock Option Plans.
	Prior to our IPO in April 2013, the Board of Directors authorized an offer to certain employee and non-employee options holders on the following terms: those holding stock options with a strike price of $25.00 or more had the opportunity to exchange their options for 60% of the number of options currently held with an exercise price equal to the IPO price, which was $10.00 per share, and those holding stock options with a strike price of $12.50 had the opportunity to exchange their options for 80% of the number of options currently held with an exercise price equal to the IPO price which was $10.00 per share. On April 5, 2013, our initial public offering became effective and 336,300 options with exercise prices ranging from $12.50 to $33.80 were exchanged for 242,070 options with an exercise price of $10.00. The options did not result in the recognition of incremental compensation cost. In addition, 53,500 options which were approved to be issued and priced at the IPO price were issued to employees with an exercise price of $10.00 per share.
	A summary of employee and non-employee stock option activity for the years ended December 31, 2014, 2013 and 2012 is as follows:
		Options Outstanding							Weighted-		Aggregate
									Average		Intrinsic
									Remaining		Value
									Contractual
		Number of			Weighted-				Term (in years)
		Shares			Average
					Exercise
					Price
	Outstanding January 1, 2012	559,990			$	12.85			8.1		$	11,737,710
	Granted	2,400			33.8
	Cancelled or expired	(9,050	)		23.43
	Outstanding December 31, 2012	553,340			$	12.76			7.13		$	1,142,432
	Granted	426,762			14.57
	Exercised	(164	)		10
	Cancelled or expired	(106,396	)		20.46
	Outstanding December 31, 2013	873,542			$	10.83			7.75		$	3,138,539
	Granted	1,154,800			$	10.41
	Exercised	(30,083	)		$	6.61
	Cancelled or expired	(158,801	)		$	11.45
	Outstanding December 31, 2014	1,839,458			$	10.58			8.49		$	618,250
	Exercisable, December 31, 2014	635,435			$	9.14			6.72		$	478,219
	Aggregate intrinsic value represents the difference between the fair value of our common stock and the exercise price of outstanding, in-the-money options. The fair value of our common stock was $6.68 and $13.78 as of December 31, 2014 and 2013, respectively, and the estimated fair value of our common stock was $9.60 as of December 31, 2012. During the year ended December 31, 2014 and 2013, we received $79,018 and $1,640, respectively from the exercise of options. Also during the year ended December 31, 2014, an option holder exercised options to purchase 12,000 shares of common stock with an exercise price of $10.00 per share using the net issue exercise method whereby the option holder surrendered 11,429 shares in payment in full of the exercise price resulting in net issuance of 571 shares of common stock. The options exercised in 2014 and 2013 had a total intrinsic value of $120,510 and $1,630, respectively. Options were not exercised in 2012.
	As of December 31, 2014, total unrecognized compensation cost related to non-vested stock options granted to employees was $6,058,774, which we expect to recognize over the next 3.70 years.
	As of December 31, 2014 and 2013, total unrecognized compensation cost related to non-vested stock options granted to non-employees was $645,739 and $94,359, respectively, which we expect to recognize over the next 2.95 and 1.78 years, respectively. The estimate of unrecognized non-employee compensation is based on the fair value of the non-vested options as of December 31, 2014 and 2013.
	The following table summarizes information about outstanding and vested stock options granted to employees and non-employees as of December 31, 2014 as follows:
		Options Outstanding									Options Vested and Exercisable
	Exercise Price	Number of			Weighted-		Weighted-				Number of		Weighted-
		Shares			Average		Average				Shares		Average
		Outstanding			Remaining		Exercise						Exercise Price
					Contractual		Price
					Life (in years)
	4	145,000			4.22		$	4			145,000		$	4
	4.8	30,914			5.05		4.8				30,432		4.8
	6.3	451,400			9.95		6.3				85,280		6.3
	7.44	7,500			9.98		7.44				—		—
	9.09	223,400			9.74		9.09				20,681		9.09
	10	230,788			5.65		10				209,395		10
	11.70 - 11.75	50,400			9.3		11.7				2,066		11.74
	12.50 - 14.18	105,700			9.01		13.99				1,351		13.98
	15.39	304,356			8.78		15.39				90,230		15.39
	15.89	200,000			9.4		15.89				37,500		15.89
	17.38	90,000			9.22		17.38				13,500		17.38
	Total	1,839,458			8.49		$	10.58			635,435		$	9.14
	The fair value of options granted to employees is estimated on the grant date using the Black-Scholes option valuation model. This valuation model for stock-based compensation expense requires us to make assumptions and judgments about the variables used in the calculation, including the fair value of our common stock (see Note 13), the expected term (the period of time that the options granted are expected to be outstanding), the volatility of our common stock, a risk-free interest rate, and expected dividends. We also estimate forfeitures of unvested stock options. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period estimates are revised. No compensation cost is recorded for options that do not vest. We use the simplified calculation of expected life described in the SEC’s Staff Accounting Bulletin No. 107, Share-Based Payment, and volatility is based on an average of the historical volatilities of the common stock of three entities with characteristics similar to those of the Company. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. We use an expected dividend yield of zero, as we do not anticipate paying any dividends in the foreseeable future. Expected forfeitures are assumed to be zero due to the plan design which has monthly vesting after an initial cliff vesting period.
	The following table presents the weighted-average assumptions used to estimate the fair value of options granted to employees during the periods presented:
		Year Ended December 31,
		2014				2013				2012
	Volatility	70.17		%		76.6		%		77.39		%
	Risk free interest rate	1.78		%		1.79		%		1.43		%
	Dividend yield	—				—				—
	Term (years)	5.98				6.14				6.5
	Weighted-average fair value of options granted during the period	$	5.29			$	9.85			$	23.35
	In 2010, we issued an aggregate of 80,000 options to non-employees with an exercise price of $25.00. As described above, on April 5, 2013, these options were exchanged for 48,000 options with an exercise price of $10.00. In October 2013, we issued 10,000 options to a non-employee with an exercise price of $15.39. In May 2014, we issued 200,000 options to a Director, with an exercise price of $15.89. See Note 17 for additional information. The following table presents the weighted-average assumptions used to estimate the fair value of options reaching their measurement date for non-employees during the periods presented:
		Year Ended December 31,
		2014			2013			2012
Volatility	71.76	%		75.68	%		75.01	%
Risk free interest rate	2.44	%		1.53	%		1.26	%
Dividend yield	—			—			—
Term (years)	9.68			7.68			8.28
Starting in 2013, restricted stock awards have been granted to employees, directors and consultants as compensation for services. At December 31, 2014, there was $852,206 of unrecognized compensation cost related to non-vested restricted stock granted to employees; we expect to recognize the cost over 3 years. At December 31, 2014, there was $12,948 of unrecognized compensation cost related to non-vested restricted stock granted to non-employees, which we expect to recognize over 0.78 years.
The following table summarizes the activities for our non-vested restricted stock awards for the years ended December 31, 2014 and 2013:
			Non-vested Restricted Stock Awards
			Number of Shares				Weighted-Average Grant Date Fair Value
Non-vested at January 1, 2013			$	—			$	—
Granted			7,500				13.5
Vested			(2,500		)		15.39
Non-vested at December 31, 2013			$	5,000			$	12.55
Granted			220,000				9.01
Vested			(80,000		)		10.19
Forfeited/canceled			(12,500		)		12.04
Non-vested at December 31, 2014			$	132,500			$	8.14
The following table presents the effects of stock-based compensation related to stock option and restricted stock awards to employees and non-employees on our Statement of Operations during the periods presented:
	Year Ended December 31,
	2014				2013				2012
Cost of revenues	$	148,852			$	41,470			$	11,753
Research and development	472,573				114,189				460,321
General and administrative	3,058,465				516,127				297,175
Sales and marketing	155,459				63,359				146,112
Total stock-based compensation	$	3,835,349			$	735,145			$	915,361

Warrants

Warrants	12 Months Ended
	Dec. 31, 2014
Warrants and Rights Note Disclosure [Abstract]
Warrants	Warrants
	We have issued certain warrants which contain an exercise price adjustment feature in the event we issue additional equity instruments at a price lower than the exercise price of the warrant. The warrants are described herein as derivative warrants. For all derivative warrants, in the event equity instruments are issued at a price lower than the exercise price of the warrant, the exercise price is adjusted to the price of the new equity instruments issued (price adjustment feature). For certain of these warrants, the number of shares underlying the warrant is also adjusted to an amount computed by dividing the proceeds of the warrant under its original terms by the revised exercise price (share adjustment feature). These warrants are initially recorded as a warrant liability at fair value with a corresponding entry to the loan guarantee fee asset, debt discount, additional paid-in capital or expense dependent upon the service provided in exchange for the warrant grant. Subsequently, any change in fair value is recognized in earnings until such time as the warrants are exercised, amended or expire. As of December 31, 2014 all warrants with a share adjustment feature have either expired or have been exercised.
	In connection with debt guarantees and extensions, we issued 1,051,506 warrants to Mr. Pappajohn, a member of our Board of Directors and stockholder, at various dates (see Note 17). These warrants were initially recorded at fair value as a loan guarantee fee amortized over the period of the guarantee to interest expense. The aggregate issue date fair value of the debt guarantee warrants was $1,555,000 in 2012, and $831,000 in 2011. There were no debt guarantee warrants issued in 2014 or 2013.
	In connection with the acquisition of a line of credit, we issued 60,000 warrants to DAM in March 2011 with an initial estimated fair value of $1,019,000. In March 2012 in exchange for an extension of that line, we issued 15,000 warrants with an initial estimated fair value of $306,000. See Note 6.
	We issued 200 warrants to a consultant for services provided in February and March 2011 and 4,000 warrants to a member of our Board of Directors in connection with the March 2011 line of credit agreement with DAM. These warrants were recorded as consulting expense at an initial estimated fair value of $69,000 and expire in March 2016.
	In connection with the December 2011 Financing Transaction we granted a total of 112,940 warrants at various dates to Mr. Pappajohn, Dr. Pecora and NNJCA. The aggregate issue date fair value of these financing fee warrants was $1,522,000 in 2012 and $951,000 in 2011. In October 2012, 37,646 of these warrants were surrendered in exchange for an increase to the prepayment penalty, and 75,294 were amended in exchange for 20,669 additional warrants with an initial estimated fair value of $606,000. Also in October 2012, Mr. Pappajohn agreed to extend a portion of the debt’s maturity date and in exchange we issued 9,412 additional warrants with an initial estimated fair value of $267,000. See Note 6.
	In connection with the 2012 Convertible Debt Financing Transaction, we granted a total of 28,235 warrants to Mr. Pappajohn and Mr. Oman with an initial estimated fair value of $1,107,000. In October 2012, these warrants were surrendered in exchange for additional financing and 114,510 new warrants with an initial estimated fair value of $4,090,000. See Note 6.
	On September 6, 2012, we extended the maturity date of warrants to purchase 70,598 shares of our common stock which were due to expire on September 10, 2012 to September 28, 2012. On September 27, 2012, we extended the maturity date of 65,328 of these warrants to September 10, 2013. In exchange, the warrants became subject to a lock-up agreement for 180 days after the consummation of an IPO on the same terms as other lock-up agreements in favor of the underwriters of an offering. We determined the fair value of the warrant extensions to be approximately $144,000, which was recorded as general and administrative expense.
	On October 22, 2012, in exchange for amending warrants issued in connection with his guarantee of the Wells Fargo debt, we issued warrants to purchase 10,157 shares of our common stock to Mr. Pappajohn with an exercise price equal to the lesser of (i) $42.50 per share and (ii) the IPO or merger price per share. These warrants were recorded as a financing fee expense at an estimated fair value of $298,000.
	In connection with the December 2012 Bridge Financing transaction, we granted 23,529 warrants to Mr. Pappajohn with an initial estimated fair value of $837,000. See Note 6.
	During 2012, warrants to purchase 54,910 shares were exercised and $690,227 was received and recorded as increases to common stock and additional paid-in capital. An additional 15,164 warrants expired unexercised. In connection with the 2012 Convertible Debt Financing Transaction, we granted 4,118 warrants to Mr. Pappajohn and 2,941 warrants to Mr. Oman on February 22, 2013. The warrants have a ten-year term and an exercise price equal to the IPO price of $10.00 per share. Pursuant to a subsequent agreement, the warrants held by Mr. Pappajohn have an exercise price of $15.00 per share. These warrants were initially recorded at fair value as a financing fee asset and were amortized over the period of the note to interest expense. The issue date fair value of these warrants was $221,000.
	In connection with the December 2012 Bridge Financing Transaction, we granted 2,353 ten-year warrants with an exercise price equal to the IPO price of $10.00 per share to Mr. Pappajohn on March 7, 2013. Mr. Pappajohn subsequently agreed that if our final IPO price was below $15.00, there would be no further adjustment to the price or number of shares covered by the warrants held by him. These warrants were initially recorded at fair value as a financing fee asset and were amortized over the period of the note to interest expense. The issue date fair value of these warrants was $47,000.
	On February 11, 2013, John Pappajohn agreed to limit certain anti-dilution rights in his warrants to purchase shares of the Company’s common stock. Subject to the consummation of an IPO prior to April 13, 2013, Mr. Pappajohn agreed that if the final IPO price was below $15.00, the exercise price of the warrants held by him would adjust to $15.00 and the number of shares underlying the warrants would be adjusted as if the IPO price were $15.00 and then there would be no further adjustment to the price or number of shares covered by warrants held by him. In February 2013, certain warrant holders agreed to waive the price and share adjustment provisions of their warrants, except for the anti-dilution provisions related to stock splits, subdivisions and combinations, with respect to an aggregate of 114,030 shares of common stock underlying such warrants, effective immediately following the consummation of our IPO on April 10, 2013 at $10.00 per share.
	On April 10, 2013, the Company completed the IPO at $10.00 per share. The shares of common stock issuable upon the exercise of warrants increased by 838,889 shares and the exercise prices of 1,656,860 warrants were adjusted as a result of share and exercise price adjustment features in certain warrants.
	On April 29, 2013, the Company received $96,000 from shareholders who exercised warrants to purchase 24,000 shares of common stock at $4.00 per share.
	On July 6, 2013, a warrant holder exercised a warrant to purchase 6,000 shares of common stock at an exercise price of $4.00 per share using the net issuance exercise method whereby 2,072 shares were surrendered as payment in full of the exercise price resulting in a net issuance of 3,928 shares.
	On July 8, 2013, the Company received $96,000 from shareholders who exercised warrants to purchase 24,000 shares of common stock at $4.00 per share.
	On September 10, 2013 and September 27, 2013, the Company extended the expiration date of 42,468 warrants for 17 days and 11 days respectively.
	On September 30, 2013, warrant holders exercised warrants to purchase 30,034 shares of common stock at an exercise price of $10.00 per share using the net issuance exercise method whereby 14,313 shares were surrendered as payment in full of the exercise price resulting in a net issuance of 15,721 shares.
	On October 7, 2013 and October 8, 2013, warrant holders exercised warrants to purchase 33,868 shares of common stock, at exercise prices ranging from $10.00 – $14.10 per share, using the net issuance exercise method whereby 23,188 shares were surrendered as payment in full of the exercise price resulting in a net issuance of 10,680 shares.
	In January 2014, the Company received $950 from a warrant holder who exercised warrants to purchase 95 shares of common stock at $10.00  per share. In February 2014 a warrant holder exercised warrants to purchase 3,320 shares of common stock at an exercise price of $10.00 per share using the net issuance exercise method whereby 1,661 shares were surrendered in payment in full of the exercise price resulting in a net issuance of 1,659 shares. In March 2014 a warrant holder exercised warrants to purchase 12,500 shares of common stock at an exercise price of $10.00 per share using the net issuance exercise method whereby 7,230 shares were surrendered in payment in full of the exercise price resulting in a net issuance of 5,270 shares. In June 2014, we received $177,154 from Mr. Pappajohn who exercised warrants to purchase 44,288 shares of common stock at an exercise price of $4.00 per share.
	In July 2014, warrant holders exercised warrants to purchase 130,000 shares of common stock at an exercise price of $4.00 per share using the net issuance exercise method whereby 45,894 shares were surrendered in payment in full of the exercise price resulting in a net issuance of 84,106 shares.
	In October 2014, 470,833 warrants expired unexercised, of which 233,333 were warrants held by Mr. Pappajohn.
	The following table summarizes the warrant activity for the years ending December 31, 2014, 2013 and 2012:
	Issued With / For		Exercise		Warrants	2012	2012		2012		2012		Warrants	2013	2013		2013		IPO		Warrants	2014		2014		Warrants
			Price		Outstanding	Warrants	Warrants		Warrants		Warrants		Outstanding	Warrants	Warrants		Warrants		Adjustments		Outstanding	Warrants		Warrants		Outstanding
					January 1,	Issued	Exercised		Surrendered		Expired		December 31,	Issued	Exercised		Expired		(E)		December 31,	Exercised		Expired		December 31,
					2012								2012								2013					2014
	Non-Derivative Warrants:
	Financing		$	10	—	—	—		—		—		—	—	—		—		243,334		243,334	—		—		243,334
	Financing		14.1		8,865	—	(2,482	)	—		(6,383	)	—	—	—		—		—		—	—		—		—
	Financing		15		—	—	—		—		—		—	—	—		—		436,079		436,079	—		—		436,079
	Debt Guarantee		4		228,288	—	—		—		—		228,288	—	(54,000	)	—		—		174,288	(174,288	)	—		—
	Debt Guarantee		10		—	—	—		—		—		—	—	—		—		237,500		237,500	—		(237,500	)	—
	Debt Guarantee		15		—	—	—		—		—		—	—	—		—		585,645		585,645	—		(233,333	)	352,312
	Series A Pref. Stock		10.75		30,000	—	(30,000	)	—		—		—	—	—		—		—		—	—		—		—
	Series A Pref. Stock		14.1		89,214	—	(18,616	)	—		(5,269	)	65,329	—	(29,868	)	(35,461	)	—		—	—		—		—
	Consulting		10		—	—	—		—		—		—	—	—		—		29,138		29,138	—		—		29,138
			13.72 F		356,367	—	(51,098	)	—		(11,652	)	293,617	—	(83,868	)	(35,461	)	1,531,696		1,705,984	(174,288	)	(470,833	)	1,060,863
	Derivative Warrants:
	Series A Pref. Stock		4.00 A		7,325	—	(3,812	)	—		(3,513	)	—	—	—		—		—		—	—		—		—
	Financing		10.00 B		—	—	—		—		—		—	—	—		—		60,000		60,000	—		—		60,000
	Financing		25.00 B		60,000	—	—		—		—		60,000	—	—		—		(60,000	)	—	—		—		—
	Financing		42.50 BCD		42,353	189,117	—		(156,176	)	—		75,294	—	—		—		(75,294	)	—	—		—		—
	Financing		42.50 AD		—	54,314	—		—		—		54,314	2,941	—		—		(57,255	)	—	—		—		—
	Financing		42.50 ACD		—	120,865	—		—		—		120,865	6,471	—		—		(127,336	)	—	—		—		—
	Debt Guarantee		10.00 A		—	—	—		—		—		—	—	—		—		12,500		12,500	(12,500	)	—		—
	Debt Guarantee		25.00 ACD		212,000	—	—		—		—		212,000	—	—		—		(212,000	)	—	—		—		—
	Debt Guarantee		25.00 AD		100,000	—	—		—		—		100,000	—	—		—		(100,000	)	—	—		—		—
	Debt Guarantee		32.45 AC		40,000	—	—		—		—		40,000	—	—		—		(40,000	)	—	—		—		—
	Debt Guarantee		42.50 ACD		—	75,392	—		(37,000	)	—		38,392	—	—		—		(38,392	)	—	—		—		—
	Debt Guarantee		42.50 BCD		—	37,000	—		—		—		37,000	—	—		—		(37,000	)	—	—		—		—
	Series B Pref. Stock		10.00 B		—	—	—		—		—		—	—	(34,034	)	—		52,464		18,430	(3,415	)	—		15,015
	Series B Pref. Stock		25.00 B		52,464	—	—		—		—		52,464	—	—		—		(52,464	)	—	—		—		—
	Consulting		10.00 B		—	—	—		—		—		—	—	—		—		200		200	—		—		200
	Consulting		12.50 AD		4,030	—	—		—		—		4,030	—	—		—		(4,030	)	—	—		—		—
	Consulting		14.10 AD		10,000	—	—		—		—		10,000	—	—		—		(10,000	)	—	—		—		—
	Consulting		25.00 BD		200	—	—		—		—		200	—	—		—		(200	)	—	—		—		—
	Consulting		25.00 AD		4,000	—	—		—		—		4,000	—	—		—		(4,000	)	—	—		—		—
			10.00 F		532,372	476,688	(3,812	)	(193,176	)	(3,513	)	808,559	9,412	(34,034	)	—		(692,807	)	91,130	(15,915	)	—		75,215
			13.47 F		888,739	476,688	(54,910	)	(193,176	)	(15,165	)	1,102,176	9,412	(117,902	)	(35,461	)	838,889		1,797,114	(190,203	)	(470,833	)	1,136,078
	_________________________
	A	These warrants are subject to fair value accounting and contain exercise price and number of share adjustment features. See Note 13.
	B	These warrants are subject to fair value accounting and contain an exercise price adjustment feature. See Note 13.
C	On February 11, 2013, these warrants held by John Pappajohn were amended to limit the adjustment feature(s) to $15.00 per share in an initial public offering (totaling 530,022 warrants).
D	The exercise price and/or number of share adjustment features of these warrants expired and are no longer subject to fair value accounting after our initial public offering.
E	On April 10, 2013 the Company completed the IPO at $10.00 per share. The shares of common stock issuable upon the exercise of warrants outstanding as of April 10, 2013 increased by 838,889 shares and the exercise prices of 1,656,860 warrants were adjusted as a result of the share and exercise price adjustment features described above.
F	Weighted average exercise prices are as of December 31, 2014.

Fair_Value_of_Warrants

Fair Value of Warrants	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value of Warrants	Fair Value of Warrants
	The following tables summarize the assumptions used in computing the fair value of derivative warrants subject to fair value accounting at the date of issue during the years ended December 31, 2014, 2013 and 2012 and at December 31, 2014, December 31, 2013 and April 5, 2013 (IPO valuation date). In computing the fair value of the warrants, if the stated exercise price of the warrants exceeded the assumed value of the Company stock at the date the fair value was being computed, the exercise price and number of shares (if applicable) underlying the warrants were adjusted to reflect an assumed trigger of the price and/or share adjustment features related to the applicable warrants. Such adjustments were only applicable to 2012 and 2013 due to the relative price of the warrants and the assumed Company stock price:
	Debt Guarantee	Exercised During the year ended December 31, 2014			Issued During the year ended December 31, 2012			As of December 31, 2013			IPO Date
											April 5, 2013
	Exercise Price	$	10		$	9.6		$	10		$	13.56
	Expected life (years)	0.6			4.66			0.83			2.42
	Expected volatility	49.01		%	80.05		%	57.33		%	66.37		%
	Risk-free interest rate	0.08		%	0.82		%	0.13		%	0.32		%
	Expected dividend yield	0		%	0		%	0		%	0		%
	Series B	Exercised During the Year Ended December 31, 2014			As of December 31,
					2014			2013
	Exercise Price	$	10		$	10		$	10
	Expected life (years)	1.72			0.88			1.92
	Expected volatility	46.6		%	49.95		%	59.26		%
	Risk-free interest rate	0.33		%	0.25		%	0.38		%
	Expected dividend yield	0		%	0		%	0		%
		As of December 31,						IPO Date
	Consulting	2014			2013			April 5, 2013
	Exercise Price	$	10		$	10		$	10
	Expected life (years)	1.14			2.14			2.33
	Expected volatility	49.25		%	62.63		%	63.2		%
	Risk-free interest rate	0.25		%	0.38		%	0.27		%
	Expected dividend yield	0		%	0		%	0		%
		Issued During						As of December 31,						IPO Date
		the Year Ended												April 5,
		December 31,
	Financing	2014			2013			2014			2013			2013
	Exercise Price	$	—		$	13.34		$	10		$	10		$	13.21
	Expected life (years)	0			9.78			1.23			2.25			8.3
	Expected volatility	—		%	74.7		%	50.23		%	64.4		%	73.22		%
	Risk-free interest rate	—		%	1.95		%	0.25		%	0.38		%	1.44		%
	Expected dividend yield	0		%	0		%	0		%	0		%	0		%
	The assumed ranges of Company stock prices used in computing the warrant fair value for warrants issued during the year is as follows: in 2014, $6.68—$19.86; in 2013, $9.60—$20.26; in 2012, $9.60—$33.80. In determining the fair value of warrants issued at each reporting date, the assumed Company stock price was $6.68 and $13.78 (the closing price on the NASDAQ Capital Market) at December 31, 2014 and 2013.
	The following table summarizes the derivative warrant activity subject to fair value accounting for the years ended December 31, 2014, 2013 and 2012:
		Issued with			Issued with			Issued For			Issued For			Issued For			Total
		Series A			Series B			Debt			Consulting			Financing
		Preferred			Preferred			Guarantee
		Stock			Stock
	Fair value of warrants outstanding as of January 1, 2012	$	220,000		$	1,160,000		$	6,993,000		$	447,000		$	2,293,000		$	11,113,000
	Fair value of warrants issued	—			—			1,583,000			—			4,961,000			6,544,000
	Fair value of warrants exercised	(55,000		)	—			—			—			—			(55,000		)
	Warrant restructuring	—			—			268,000			—			2,217,000			2,485,000
	Change in fair value of warrants	(165,000		)	(930,000		)	(3,165,000		)	(300,000		)	(2,978,000		)	(7,538,000		)
	Fair value of warrants outstanding as of December 31, 2012	—			230,000			5,679,000			147,000			6,493,000			12,549,000
	Fair value of warrants issued	—			—			—			—			268,000			268,000
	Fair value of warrants exercised	—			(420,000		)	—			—			—			(420,000		)
	Reclassification to equity in IPO	—			—			(2,514,000		)	(108,000		)	(4,548,000		)	(7,170,000		)
	Change in fair value of warrants	—			307,000			(3,101,000		)	(38,000		)	(1,801,000		)	(4,633,000		)
	Fair value of warrants outstanding as of December 31, 2013	—			117,000			64,000			1,000			412,000			594,000
	Fair value of warrants exercised	—			(38,000		)	(87,000		)	—			—			(125,000		)
	Change in fair value of warrants	—			(71,000		)	23,000			(1,000		)	(368,000		)	(417,000		)
	Fair value of warrants outstanding as of December 31, 2014	$	—		$	8,000		$	—		$	—		$	44,000		$	52,000

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The Fair Value Measurements and Disclosures Topic of the FASB Accounting Standards Codification requires the use of valuation techniques that are consistent with the market approach, the income approach and/or the cost approach. Inputs to valuation techniques refer to the assumptions that market participants would use in pricing the asset or liability. Inputs may be observable, meaning those that reflect the assumptions market participants would use in pricing the asset or liability developed based on market data obtained from independent sources, or unobservable, meaning those that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. In that regard, the Topic establishes a fair value hierarchy for valuation inputs that give the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.
	The fair value hierarchy is as follows:
	Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets that we have the ability to access as of the measurement date.
	Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.
	Level 3: Significant unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing an asset or liability.
	The following table summarizes the financial liabilities measured at fair value on a recurring basis segregated by the level of valuation inputs within the fair value hierarchy utilized to measure fair value:
		2014
		Total			Quoted Prices in		Significant Other	Significant
					Active Markets for		Observable	Unobservable
					Identical Assets		Inputs	Inputs
					(Level 1)		(Level 2)	(Level 3)
	Warrant liability	$	52,000		—		—	$	52,000
	Gentris contingent consideration	293,400			—		—	293,400
	Notes payable to VenturEast	534,828			—		—	534,828
		$	880,228		—		—	$	880,228
		2013
		Total			Quoted Prices in		Significant Other	Significant
					Active Markets for		Observable	Unobservable
					Identical Assets		Inputs	Inputs
					(Level 1)		(Level 2)	(Level 3)
	Warrant liability	$	594,000		—		—	$	594,000
	The warrant liability consists of stock warrants we issued that contain an exercise price adjustment feature. In accordance with derivative accounting for warrants, we calculated the fair value of warrants and the assumptions used are described in Note 13, “Fair Value of Warrants”. Realized and unrealized gains and losses related to the change in fair value of the warrant liability are included in other income (expense) on the Consolidated Statement of Operations.
	The value of the Gentris contingent consideration was determined using a discounted cash flow of the expected payments required by the purchase agreement.
	The ultimate payment to VenturEast will be the value of 84,278 shares of common stock at the time of payment. The value of the note payable to VenturEast was determined using the fair value of our common stock less a discount for credit risk. During the year ended December 31, 2014 we recognized a gain of $198,000 due to the decrease in value of the note. Realized and unrealized gains and losses related to the change in fair value of the note are included in other income (expense) on the Consolidated Statement of Operations.
	A table summarizing the activity for the derivative warrant liability which is measured at fair value using Level 3 inputs is presented in Note 13. The following table summarizes the activity of the notes payable to VenturEast and Gentris contingent consideration which were measured at fair value using Level 3 inputs:
		Note Payable			Gentris Contingent
		to VenturEast			Consideration
	Fair value at January 1, 2014	$	—		$	—
	Fair value at issuance	733,387			293,400
	Change in fair value	(198,559		)	—
	Fair value at December 31, 2014	$	534,828		$	293,400

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies
	In the normal course of business, the Company is involved in various claims and legal proceedings. In the opinion of management, the ultimate liability or disposition thereof is not expected to have a material adverse effect on our financial condition, results of operations or liquidity.

Joint_Venture_Agreement

Joint Venture Agreement	12 Months Ended
	Dec. 31, 2014
Equity Method Investments and Joint Ventures [Abstract]
Joint Venture Agreement	Joint Venture Agreement
	In November 2011, we entered into an affiliation agreement with the Mayo Foundation for Medical Education and Research (“Mayo”), subsequently amended. Under the agreement, we formed a joint venture with Mayo in May 2013 to focus on developing oncology diagnostic services and tests utilizing next generation sequencing. The joint venture is a limited liability company, with each party initially holding fifty percent of the issued and outstanding membership interests of the new entity (the “JV”). In exchange for our membership interest in the JV, we made an initial capital contribution of $1.0 million in October 2013. In addition, we issued 10,000 shares of our common stock to Mayo pursuant to our affiliation agreement and recorded an expense of approximately $175,000. We also recorded additional expense of approximately $231,000 during the fourth quarter of 2013 related to shares issued to Mayo in November of 2011 as the JV achieved certain performance milestones. In the third quarter of 2014 we made an additional $1.0 million capital contribution.
	The agreement also requires aggregate total capital contributions by us of up to an additional $4.0 million. We currently anticipate that we will make capital contributions of $1.0 million in the second quarter of 2015. The timing of the remaining installments is subject to the JV's achievement of certain operational milestones agreed upon by the board of governors of the JV. In exchange for its membership interest, Mayo’s capital contribution will take the form of cash, staff, services, hardware and software resources, laboratory space and instrumentation, the fair market value of which will be approximately equal to $6.0 million. Mayo’s continued contribution will also be conditioned upon the JV’s achievement of certain milestones.
	The joint venture is considered a variable interest entity under ASC 810-10, but we are not the primary beneficiary as we do not have the power to direct the activities of the joint venture that most significantly impact its performance. Our evaluation of ability to impact performance is based on our equal board membership and voting rights and day to day management functions which are performed by the Mayo personnel.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions
	John Pappajohn, a member of the Board of Directors and stockholder, had personally guaranteed our revolving line of credit with Wells Fargo Bank through March 31, 2014. As consideration for his guarantee, as well as each of the eight extensions of this facility through March 31, 2014, Mr. Pappajohn received warrants to purchase an aggregate of 1,051,506 shares of common stock of which Mr. Pappajohn assigned warrants to purchase 284,000 shares of common stock to certain third parties. Through December 31, 2014, warrants to purchase 440,113 shares of common stock have been exercised by Mr. Pappajohn and 233,333 warrants to purchase common stock have expired. After adjustment pursuant to the terms of the warrants in conjunction with our IPO, the number of these warrants outstanding retained by Mr. Pappajohn was 352,312 at $15.00 per share on December 31, 2014.
	In addition, John Pappajohn also had loaned us an aggregate of $6,750,000 (all of which was converted into 675,000 shares of common stock at the IPO price of $10.00 per share). In connection with these loans, Mr. Pappajohn received warrants to purchase an aggregate of 202,630 shares of common stock. After adjustment pursuant to the terms of the warrants in conjunction with our IPO, the number of warrants outstanding was 436,079 at $15.00 per share at December 31, 2014.
	Effective January 6, 2014, the board of directors appointed John Pappajohn to serve as the Chairman of the Board, a position previously held by Dr. Raju S.K. Chaganti. As compensation for serving as the Chairman of the Board, the Company will pay Mr. Pappajohn $100,000 per year and granted to Mr. Pappajohn 25,000 restricted shares of the Company's common stock, and options to purchase an aggregate of 100,000 shares of the Company's common stock. The options have a term of ten years from the date on which they were granted. The restricted stock and the options each vest in two equal installments on the one year anniversary and the two year anniversary of the date on which Mr. Pappajohn became the Chairman of the Board.
	In August 2010, we entered into a consulting agreement with Equity Dynamics, Inc. (“EDI”), an entity controlled by John Pappajohn, pursuant to which EDI received a monthly fee of $10,000. The consulting agreement was terminated effective March 31, 2014. Subsequently the Company entered into a new consulting agreement with EDI effective April 1, 2014 pursuant to which it will receive a monthly fee of $10,000. We expensed $120,000 annually for the years ended December 31, 2014, 2013 and 2012 related to this agreement.
	On May 19, 2006, we issued a convertible promissory note in favor of our then Chairman and founder, Dr. Chaganti, the holder, which obligated us to pay the holder the sum of $100,000, together with interest at the rate of 8.5% per annum, due April 1, 2014. Interest expense was $2,400 and $8,400 for the years ended December 31, 2013 and 2012, respectively. On April 10, 2013 the note and accrued interest converted into 13,430 shares of common stock at the IPO price of $10.00 per share. Pursuant to a consulting and advisory agreement, Dr. Chaganti also received options to purchase a total of 36,000 shares of common stock at a price of $10.00 per share which vested over a two year period. Total non-cash stock-based compensation recognized under the consulting agreement for the years ended December 31, 2014, 2013 and 2012 was $0, $76,220 and $430,600, respectively. Additionally, on September 15, 2010, we entered into a three year consulting agreement with Dr. Chaganti which was subsequently renewed through December 31, 2016 pursuant to which Dr. Chaganti receives $5,000 per month for providing consulting and technical support services. Total expenses for each of the years ended December 31, 2014, 2013 and 2012 were $60,000. Pursuant to the terms of the renewed consulting agreement, Dr. Chaganti received an option to purchase 200,000 shares of our common stock at a purchase price of $15.89 per share vesting over a period of four years. Total non-cash stock-based compensation recognized under this consulting agreement for the years ended December 31, 2014, 2013 and 2012 were $341,000, $0 and $0. Also pursuant to the consulting agreement, Dr. Chaganti assigned to us all rights to any inventions which he may invent during the course of rendering consulting services to us. In exchange for this assignment, if the USPTO issues a patent for an invention on which Dr. Chaganti is listed as an inventor, we are required to pay Dr. Chaganti (i) a one-time payment of $50,000 and (ii)1% of any net revenues we receive from any licensed sales of the invention. In 2014 we paid Dr. Chaganti $150,000 which was recognized as an expense in fiscal 2013 when three patents were issued. Also in February 2015, we paid Dr. Chaganti $150,000 for which was recognized as an expense in 2014 when three additional patents were issued.
	Andrew Pecora (indirectly through an investment company), when a member of our board of directors, and NNJCA, a limited liability company of which Dr. Pecora is a member originally provided $0.5 and $1.5 million of financing, respectively, under a Credit Agreement dated as of December 21, 2011, as amended and restated as of February 13, 2012. On April 10, 2013, NNJCA converted $0.5 million of its outstanding indebtedness into 50,000 shares of our common stock at the IPO price of $10.00 per share concurrent with our IPO. On August 19, 2013, the remaining principal under these notes were repaid to Dr. Pecora and NNJCA using a portion of the proceeds from our Secondary Offering. The loan bore an annual interest rate equal to the prime rate plus 6.25% (9.50% at August 19, 2013). We paid a pre-payment penalty due to Pecora and NNJCA of $130,000 of which $32,667 was paid upon conversion of the notes and the remaining balance paid on August 19, 2013.
	On August 15, 2010, we entered into a two-year consulting agreement with Dr. Pecora, then a member of our board of directors, pursuant to which Dr. Pecora received $5,000 per month for providing consulting and advisory services. The cash component of this agreement was terminated by mutual consent in August 2011. Dr. Pecora also received stock options under the consulting and advisory agreement to purchase a total of 12,000 shares of common stock at price of $25.00 per share which vested over a two year period. Total expenses for 2014, 2013 and 2012 under the consulting agreement were $0 , $0, $142,740, respectively, expensed under the stock option plan.
	In February 2012, we granted 28,235 warrants proportionately to Pecora and NNJCA upon their funding of $0.5 million and $1.5 million, respectively, under a new Credit Agreement. (See Notes 6 and 12). On May 15, 2012 and on August 14, 2012, we issued 4,706 of these warrants proportionately to Pecora and NNJCA (Notes 6 and 12). On October 15, 2012, Dr. Pecora and NNJCA agreed to surrender warrants to purchase an aggregate of 37,646 shares of our common stock issued in connection with this transaction in exchange for an amendment to increase the pre-payment penalties by $130,000.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation: We prepare our financial statements on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.
Segment Reporting	Segment Reporting: Operating segments are defined as components of an enterprise about which separate discrete information is used by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. We view our operations and manage our business in one operating segment, which is the business of developing and selling diagnostic tests.
Liquidity	Liquidity: Our primary sources of liquidity have been funds generated from our debt financings and equity financings. In addition, we have generated funds from the following sources: (i) cash collections from our customers; (ii) grants from the National Institutes of Health and (iii) the sale of State of New Jersey net operating loss carryforwards.
Principles of consolidation	Principles of consolidation: The accompanying consolidated financial statements include the accounts of Cancer Genetics, Inc. and our wholly owned subsidiaries, Cancer Genetics Italia S.r.l (“CGI Italia”), Gentris LLC (from July 16, 2014) and CGI India (BioServe) (from August 18, 2014).
	All significant intercompany account balances and transactions have been eliminated in consolidation.
Use of estimates and assumptions	Use of estimates and assumptions: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates made by management include, among others, realization of amounts billed, realization of long-lived assets, realization of intangible assets, accruals for litigation and registration payments, assumptions used to value stock options, warrants and goodwill and the valuation of assets acquired and liabilities assumed from acquisitions. Actual results could differ from those estimates.
Risks and uncertainties	Risks and uncertainties: We operate in an industry that is subject to intense competition, government regulation and rapid technological change. Our operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory, foreign operations, and other risks, including the potential risk of business failure.
Cash and cash equivalents	Cash and cash equivalents: Highly liquid investments with original maturities of three months or less when purchased are considered to be cash equivalents. Financial instruments which potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents. We maintain cash and cash equivalents with high-credit quality financial institutions. At times, such amounts may exceed insured limits. We have not experienced any losses in such accounts and believe we are not exposed to any significant credit risk on our cash and cash equivalents.
Revenue recognition	Revenue recognition: Revenue is recognized in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605, Revenue Recognition, and ASC 954-605 Health Care Entities, Revenue Recognition which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the customer or services have been rendered; (3)the price is fixed or determinable; and (4) collectability is reasonably assured. In determining whether the price is fixed or determinable, we consider payment limits imposed by insurance carriers and Medicare and the amount of revenue recorded takes into account the historical percentage of revenue we have collected for each type of test for each payor category. Periodically, an adjustment is made to revenue to record differences between our anticipated cash receipts from insurance carriers and Medicare and actual receipts from such payors. For the periods presented, such adjustments were not significant. For some Clinical Service and Biopharma customers billed directly, revenue is recorded based upon the contractually agreed upon fee schedule. When assessing collectability, we consider whether we have sufficient payment history to reliably estimate a payor’s individual payment patterns. For new tests where there is no evidence of payment history at the time the tests are completed, we only recognize revenues once reimbursement experience can be established. We then recognize revenue equal to the amount of cash received. We do not bill customers for shipping and handling fees and do not collect any sales or other taxes.
	Revenues from grants to support product development are recognized when costs and expenses under the terms of the grant have been incurred and payments under the grants become contractually due.
Accounts receivable	Accounts receivable: Accounts receivable are carried at original invoice amount less an estimate for contractual adjustments and doubtful receivables, the amounts of which are determined by an analysis of individual accounts. Our policy for assessing the collectability of receivables is dependent upon the major payor source of the underlying revenue. For direct bill clients, an assessment of credit worthiness is performed prior to initial engagement and is reassessed periodically. If deemed necessary, an allowance is established on receivables from direct bill clients. For insurance carriers where there is not an established pattern of collection, revenue is not recorded until cash is received. For receivables where insurance carriers have made payments to patients instead of directing payments to the Company, an allowance is established for a portion of such receivables. After reasonable collection efforts are exhausted, amounts deemed to be uncollectible are written off against the allowance for doubtful accounts. Since the Company only recognizes revenue to the extent it expects to collect such amounts, bad debt expense related to receivables from patient service revenue is recorded in general and administrative expense in the consolidated statement of operations. Recoveries of accounts receivable previously written off are recorded when received.
Deferred revenue	Deferred revenue: Payments received in advance of services rendered are recorded as deferred revenue and are subsequently recognized as revenue in the period in which the services are performed.
Fixed assets	Fixed assets: Fixed assets consist of diagnostic equipment, furniture and fixtures and leasehold improvements. Fixed assets are carried at cost and are depreciated using the straight-line method over the estimated useful lives of the assets, which generally range from five to seven years. Leasehold improvements are depreciated over the lesser of the lease term or the estimated useful lives of the improvements using the straight-line method. Repairs and maintenance are charged to expense as incurred while improvements are capitalized. Upon sale, retirement or disposal of fixed assets, the accounts are relieved of the cost and the related accumulated depreciation with any gain or loss recorded to the consolidated statement of operations.
	Fixed assets are reviewed for impairment whenever changes in circumstances indicate that the carrying amount of an asset may not be recoverable. These computations utilize judgments and assumptions inherent in our estimate of future cash flows to determine recoverability of these assets. If our assumptions about these assets were to change as a result of events or circumstances, we may be required to record an impairment loss.
Goodwill	Goodwill: Goodwill resulted from the purchases of Gentris and BioServe in 2014 as described in Note 1. In accordance with ASC 350, Intangibles - Goodwill and Other, we are required to test goodwill for impairment and adjust for impairment losses, if any, at least annually and on an interim basis if an event or circumstance indicates that it is likely impairment has occurred. Our annual goodwill impairment testing date is October 1 of each year.
Loan guarantee and financing fees	Loan guarantee and financing fees: Loan guarantee fees are amortized on a straight-line basis over the term of the guarantee. Financing fees are amortized using the effective interest method over the term of the related debt.
Warrant liability	Warrant liability: We have issued certain warrants which contain an exercise price adjustment feature in the event we issue additional equity instruments at a price lower than the exercise price of the warrant. The warrants are described herein as derivative warrants. We account for these derivative warrants as liabilities. These common stock purchase warrants do not trade in an active securities market, and as such, we estimate the fair value of these warrants using the binomial lattice valuation pricing model with the assumptions as follows: The risk-free interest rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve. The expected life of the warrants is based upon the contractual life of the warrants. Volatility is estimated based on an average of the historical volatilities of the common stock of four entities with characteristics similar to those of the Company. Prior to our IPO, the measurement date fair value of the underlying common shares was based upon an external valuation of our shares. (See Notes 12 and 13). Subsequent to the IPO and Secondary Offering, we used the closing price of our shares on the OTC Bulletin Board and the NASDAQ Capital Market, respectively.
	We compute the fair value of the warrant liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the warrant liability is our stock price, which is subject to significant fluctuation and is not under our control. The resulting effect on our net income (loss) is therefore subject to significant fluctuation and will continue to be so until the warrants are exercised, amended or expire. Assuming all other fair value inputs remain constant, we will record non-cash expense when the stock price increases and non-cash income when the stock price decreases.
Income taxes	Income taxes: Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due plus deferred income taxes. Deferred income taxes are recognized for temporary differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future. Deferred income taxes are also recognized for net operating loss carryforwards that are available to offset future taxable income and research and development credits.
	Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. We have established a full valuation allowance on our deferred tax assets as of December 31, 2014 and 2013, therefore we have not recognized any tax benefit or expense in the periods presented.
	ASC 740, Income Taxes, clarifies the accounting for uncertainty in income taxes recognized in the financial statements. ASC 740 provides that a tax benefit from uncertain tax positions may be recognized when it is more-likely-than-not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. ASC 740 also provides guidance on measurement, de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. At December 31, 2014 and 2013 we had no uncertain tax positions.
	Our policy is to recognize interest and/or penalties related to income tax matters in income tax expense.
Patents	Patents: We account for intangible assets under ASC 350-30. Patents consist of legal fees incurred and are recorded at cost and amortized over the useful lives of the assets, using the straight-line method. Certain patents are in the legal application process and therefore are not currently being amortized. We review the carrying value of patents at the end of each reporting period.
Research and development	Research and development: Research and development costs associated with service and product development include direct costs of payroll, employee benefits, stock-based compensation and supplies and an allocation of indirect costs including rent, utilities, depreciation and repairs and maintenance. All research and development costs are expensed as they are incurred.
Registration payment arrangements	Registration payment arrangements: We account for our obligations under registration payment arrangements in accordance with ASC 825-20, Registration Payment Arrangements. ASC 825-20 requires us to record a liability if we determine a registration payment is probable and if it can reasonably be estimated.
Stock-based compensation	Stock-based compensation: Stock-based compensation is accounted for in accordance with the provisions of ASC 718, Compensation-Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. We estimate the fair value of stock-based awards on the date of grant using the Black-Scholes option pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. See additional information in Note 11.
	All issuances of stock options or other issuances of equity instruments to employees as the consideration for services received by us are accounted for based on the fair value of the equity instrument issued.
	We account for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity Based Payments to Non-Employees. Under ASC 505-50, we determine the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Stock-based compensation awards issued to non-employees are recorded in expense and additional paid-in capital in stockholders’ equity (deficit) over the applicable service periods based on the fair value of the awards or consideration received at the vesting date.
Fair value of financial instruments	Fair value of financial instruments: The carrying amount of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses, approximate their estimated fair values due to the short term maturities of those financial instruments. These financial instruments are considered Level 1 measurements under the fair value hierarchy. The fair values of our notes payable, lines of credit and capital leases approximate carrying value under Level 2 of the fair value hierarchy.
Joint venture accounted for under the equity method	Joint venture accounted for under the equity method: The Company records its joint venture investment following the equity method of accounting, reflecting its initial investment in the joint venture and its share of the joint venture’s net earnings or losses and distributions.
Subsequent events	Subsequent events: We have evaluated potential subsequent events through the date the financial statements were issued.
New accounting pronouncement	Recent Accounting Pronouncements: In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), requiring an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The updated standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either a full retrospective or retrospective with cumulative effect transition method. Early adoption is not permitted. The updated standard becomes effective for the Company in the first quarter of fiscal year 2017.  The Company has not yet selected a transition method and is currently evaluating the effect that the updated standard will have on the consolidated financial statements.
Earnings (loss) per share	Earnings (loss) per share: Basic earnings (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares assumed to be outstanding during the period of computation. Diluted earnings per share is computed similar to basic earnings per share except that the numerator is adjusted for the change in fair value of the warrant liability (only if dilutive) and the denominator is increased to include the number of dilutive potential common shares outstanding during the period using the treasury stock method.

Organization_Acquisitions_Desc1

Organization, Acquisitions, Description of Business, Reverse Stock Split and Charter Amendment (Tables)	12 Months Ended
	Dec. 31, 2014
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Information	The following table provides certain proforma financial information for the Company as if the acquisitions discussed above occurred on January 1, 2012:
		Unaudited
		Year Ended December 31,
		2014			2013			2012
	Revenue	$	14,365,402		$	15,767,519		$	12,528,553
	Net loss	(18,498,333		)	(13,677,432		)	(7,918,262		)
	Basic net loss per share	$	(1.94	)	$	(2.82	)	$	(5.20	)
	Dilutive net loss per share	(1.98		)	(3.77		)	(10.13		)
Gentris Corporation
Business Acquisition [Line Items]
Schedule of Business Acquisitions, by Acquisition	The total consideration for the Gentris acquisition is as follows:
		Amount
	Cash paid at closing	$	3,250,000
	Issuance of 147,843 common shares	1,271,745
	Estimated fair value of contingent consideration	293,400
	Total Purchase Price	$	4,815,145
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	he preliminary allocation of the total purchase price to the fair value of the assets acquired and liabilities assumed as of July 16, 2014 are as follows:
		Amount
	Accounts receivable	$	1,869,097
	Other current assets	265,612
	Current liabilities	(785,246		)
	Deferred revenue, long-term	(937,773		)
	Fixed Assets	1,950,885
	Goodwill	2,452,570
	Total Purchase Price	$	4,815,145
Bio Serve Biotechnologies India Private Limited
Business Acquisition [Line Items]
Schedule of Business Acquisitions, by Acquisition	The aggregate purchase price is as follows:
		Amount
	Cash paid at closing	$	72,907
	Notes payable due 12-18 months after closing	23,708
	Notes payable (value of 84,278 common shares)	733,387
	Issuance of 31,370 common shares	244,247
	Total Purchase Price	$	1,074,249
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The preliminary allocation of the total purchase price to the fair value of the assets acquired and liabilities assumed as of August 18, 2014 are as follows:
		Amount
	Accounts receivable	$	151,002
	Other current assets	120,528
	Fixed Assets	624,948
	Other assets	416,869
	Goodwill	541,565
	Current liabilities	(758,614		)
	Other liabilities	(22,049		)
	Total Purchase Price	$	1,074,249

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Computation of Basic Net Income (Loss) and Diluted Net Loss per Share Data	Basic net loss and diluted net loss per share data were computed as follows:
		2014			2013			2012
	Numerator:
	Net (loss) for basic earnings per share	$	(16,642,919	)	$	(12,372,553	)	$	(6,665,627	)
	Less change in fair value of warrant liability	417,000			4,633,000			7,538,000
	Net (loss) for diluted earnings per share	$	(17,059,919	)	$	(17,005,553	)	$	(14,203,627	)
	Denominator:
	Weighted-average basic common shares outstanding	9,449,189			4,665,316			1,342,174
	Assumed conversion of dilutive securities:
	Common stock purchase warrants	12,474			10,658			3,987
	Potentially dilutive common shares	12,474			10,658			3,987
	Denominator for diluted earnings per share—adjusted weighted-average shares	9,461,663			4,675,974			1,346,161
	Basic net loss per share	$	(1.76	)	$	(2.65	)	$	(4.97	)
	Diluted net loss per share	$	(1.80	)	$	(3.64	)	$	(10.55	)
Summary of Potentially Dilutive Adjustments to Weighted Average Number of Common Shares Excluded from Calculation	The following table summarizes potentially dilutive adjustments to the weighted average number of common shares which were excluded from the calculation:
		2014			2013			2012
	Common stock purchase warrants	$	1,060,863		$	1,701,984		$	1,102,176
	Stock options	1,839,458			873,542			553,340
	Restricted shares of common stock	132,500			7,500			—
	Common shares issuable upon conversion of Series A Preferred Stock	—			—			352,614
	Common shares issuable upon conversion of Series B Preferred Stock	—			—			364,320
		$	3,032,821		$	2,583,026		$	2,372,450
Schedule of Goodwill
	Goodwill
	Balance, December 31, 2013	$	—
	Purchased through acquisitions	2,994,135
	Balance, December 31, 2014	$	2,994,135

Revenue_and_Accounts_Receivabl1

Revenue and Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2014
Receivables [Abstract]
Schedule of Revenue by Payor Type	Revenue by service type for each of the years ended December 31 is comprised of the following:
		2014				2013				2012
	Biopharma Services	$	5,605,780			$	2,650,285			$	578,505
	Clinical Services	4,432,272				3,662,795				3,166,118
	Discovery Services	161,335				—				—
	Grants	—				296,877				556,940
		$	10,199,387			$	6,609,957			$	4,301,563
Schedule of Accounts Receivable	Accounts receivable by service type at December 31, 2014 and 2013 consists of the following:
		2014				2013
	Biopharma Services	$	3,203,335			$	428,341
	Clinical Services	1,925,176				1,174,698
	Discovery Services	151,285				—
	Allowance for doubtful accounts	(251,176		)		(36,000		)
		$	5,028,620			$	1,567,039
	Allowance for Doubtful Accounts
	Balance, December 31, 2012	$	36,000
	Additions to Allowance for doubtful accounts	—
	Deductions to Allowance for doubtful accounts	—
	Balance, December 31, 2013	36,000
	Additions to Allowance for doubtful accounts	215,176
	Deductions to Allowance for doubtful accounts	—
	Balance, December 31, 2014	$	251,176
Schedule of Product Information	The breakdown of our Clinical Services revenue (as a percent of total revenue) is as follows:
		2014			2013			2012
	Medicare	11	%		13	%		18	%
	Other insurers	16	%		25	%		32	%
	Other healthcare facilities	16	%		18	%		24	%
	Total Clinical Services	43	%		55	%		74	%

Other_Current_Assets_Tables

Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Current Assets	At December 31, 2014 and 2013, other current assets consisted of the following:
		2014		2013
	Inventory	$	279,894	$	198,789
	Prepaid expenses	911,320		593,950
	Grants receivable	—		71,877
		$	1,191,214	$	864,616

Lease_Commitments_Tables

Lease Commitments (Tables)	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
Minimum Future Lease Payments Under All Capital and Operating Leases	Minimum future lease payments under all capital and operating leases as of December 31, 2014 are as follows:
		Capital		Operating		Total
		Leases		Leases
	December 31,
	2015	$	74,280	$	854,195	$	928,475
	2016	74,280		862,957		937,237
	2017	61,625		870,407		932,032
	2018	59,094		360,140		419,234
	2019	59,094		320,885		379,979
	Thereafter	83,800		135,075		218,875
	Total minimum lease payments	$	412,173	$	3,403,659	$	3,815,832
	Less amount representing interest	52,838
	Present value of net minimum obligations	359,335
	Less current obligation under capital lease	58,950
	Long-term obligation under capital lease	$	300,385

Notes_Payable_and_Lines_of_Cre1

Notes Payable and Lines of Credit (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Summary of Short-Term and Long-Term Debt Obligations	Below is a summary of our short-term and long-term debt obligations as of December 31, 2014 and 2013:
			December 31,		December 31,
			2014		2013
	Secured Note Payable, short-term		$	—	$	22,298
	Notes Payable, Current Portion		$	—	$	22,298
	Line of Credit, Current Portion		$	—	$	6,000,000
	Lines of Credit, Current Portion		$	—	$	6,000,000
	Lines of Credit, Long-Term		$	6,000,000
	Lines of Credit, Long-Term		$	6,000,000	$	—
Conversion of Indebtedness into Shares of Common Stock	On April 10, 2013, we completed our IPO and converted the following indebtedness into shares of common stock at the IPO price of $10.00 per share:
			Converted Amount		Common Shares
	December 2011 Financing Transaction		$	4,500,000	450,000
	2012 Convertible Debt Financing Transaction		3,000,000		300,000
	December 2012 Bridge Financing Transaction		1,000,000		100,000
	Business Lines of Credit (DAM)		1,000,000		100,000
	Other Note Payable and accrued interest		134,300		13,430
			$	9,634,300	963,430
Loss on Debt and Warrant Restructuring	In connection with these transactions, we recognized a loss on debt and warrant restructuring during 2012 as presented below:
	Restated 2012 convertible debt financing transaction	$	1,506,512
	Amend warrants granted for guarantee of business line of credit	268,000
	Amend warrants granted for 2011 convertible debt financing transaction	545,000
	Settle warrants granted for guarantee of business line of credit	(129,500		)
	Settle warrants granted for 2011 convertible debt financing transaction	(328,000		)
	Loss on debt and warrant restructuring - 2012	$	1,862,012

Fixed_Assets_Tables

Fixed Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets are summarized by major classifications as follows:
		2014			2013
	Equipment	$	5,913,928		$	2,513,066
	Furniture and fixtures	548,093			461,119
	Leasehold improvements	869,578			595,689
		7,331,599			3,569,874
	Less accumulated depreciation	(2,885,006		)	(2,305,250		)
	Net fixed assets	$	4,446,593		$	1,264,624

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Reconciliation	The provision for income taxes for the years ended December 31, 2014, 2013 and 2012 differs from the approximate amount of income tax benefit determined by applying the U.S. federal income tax rate to pre-tax loss, due to the following:
		For the Year Ended December 31, 2014						For the Year Ended December 31, 2013					For the Year Ended December 31, 2012
		Amount			% of			Amount			% of		Amount			% of
					Pretax						Pretax					Pretax
					Loss						Loss					Loss
	Income tax benefit at federal statutory rate	$	(6,648,000	)	35	%		$	(4,563,000	)	35	%	$	(2,333,000	)	35	%
	State tax provision, net of federal tax benefit	(807,000		)	4.2	%		(359,000		)	2.8	%	(661,000		)	9.5	%
	Tax credits	(154,000		)	0.8	%		(126,000		)	1	%	(82,000		)	1.1	%
	Stock based compensation permanent differences	207,000			-1.1	%		229,000			-1.8	%	85,000			-1.2	%
	Derivative warrant permanent differences	(146,000		)	0.8	%		(1,622,000		)	12.4	%	(1,926,000		)	26	%
	Investor consideration permanent differences	(69,000		)	0.4	%		—			—	%	—			—	%
	Debt and warrant conversion costs permanent difference	—			—	%		3,454,000			-26.5	%	—			—	%
	Change in valuation allowance	5,255,000			-27.7	%		2,356,000			-18.1	%	4,858,000			-70.2	%
	Other	12,000			—	%		(33,000		)	0.3	%	59,000			-0.2	%
	Income tax (benefit) provision	$	(2,350,000	)	12.4	%		$	(664,000	)	5.1	%	$	—		—	%
Components of Approximate Deferred Tax	Approximate deferred taxes consist of the following components as of December 31, 2014 and 2013:
		2014			2013
	Deferred tax assets:
	Net operating loss carryforwards	$	20,982,000		$	17,140,000
	Accruals and reserves	773,000			509,000
	Non-qualified stock options	1,912,000			877,000
	Research and development tax credits	758,000			603,000
	Derivative warrant liability	26,000			26,000
	Investment in joint venture	163,000			163,000
	Goodwill	23,000			—
	Other	6,000			5,000
	Total deferred tax assets	24,643,000			19,323,000
	Less valuation allowance	(24,558,000		)	(19,303,000		)
	Net deferred tax assets	85,000			20,000
	Deferred tax liabilities:
	Fixed assets	(85,000		)	(20,000		)
	Net deferred taxes	$	—		$	—

Stock_Option_Plans_Tables

Stock Option Plans (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Employee and Nonemployee Stock Option Activity	A summary of employee and non-employee stock option activity for the years ended December 31, 2014, 2013 and 2012 is as follows:
		Options Outstanding							Weighted-		Aggregate
									Average		Intrinsic
									Remaining		Value
									Contractual
		Number of			Weighted-				Term (in years)
		Shares			Average
					Exercise
					Price
	Outstanding January 1, 2012	559,990			$	12.85			8.1		$	11,737,710
	Granted	2,400			33.8
	Cancelled or expired	(9,050	)		23.43
	Outstanding December 31, 2012	553,340			$	12.76			7.13		$	1,142,432
	Granted	426,762			14.57
	Exercised	(164	)		10
	Cancelled or expired	(106,396	)		20.46
	Outstanding December 31, 2013	873,542			$	10.83			7.75		$	3,138,539
	Granted	1,154,800			$	10.41
	Exercised	(30,083	)		$	6.61
	Cancelled or expired	(158,801	)		$	11.45
	Outstanding December 31, 2014	1,839,458			$	10.58			8.49		$	618,250
	Exercisable, December 31, 2014	635,435			$	9.14			6.72		$	478,219
Summary of Outstanding and Vested Stock Options Granted	The following table summarizes information about outstanding and vested stock options granted to employees and non-employees as of December 31, 2014 as follows:
		Options Outstanding									Options Vested and Exercisable
	Exercise Price	Number of			Weighted-		Weighted-				Number of		Weighted-
		Shares			Average		Average				Shares		Average
		Outstanding			Remaining		Exercise						Exercise Price
					Contractual		Price
					Life (in years)
	4	145,000			4.22		$	4			145,000		$	4
	4.8	30,914			5.05		4.8				30,432		4.8
	6.3	451,400			9.95		6.3				85,280		6.3
	7.44	7,500			9.98		7.44				—		—
	9.09	223,400			9.74		9.09				20,681		9.09
	10	230,788			5.65		10				209,395		10
	11.70 - 11.75	50,400			9.3		11.7				2,066		11.74
	12.50 - 14.18	105,700			9.01		13.99				1,351		13.98
	15.39	304,356			8.78		15.39				90,230		15.39
	15.89	200,000			9.4		15.89				37,500		15.89
	17.38	90,000			9.22		17.38				13,500		17.38
	Total	1,839,458			8.49		$	10.58			635,435		$	9.14
Weighted-Average Assumptions Used to Estimate Fair Value of Options Granted	The following table presents the weighted-average assumptions used to estimate the fair value of options reaching their measurement date for non-employees during the periods presented:
		Year Ended December 31,
		2014			2013			2012
	Volatility	71.76	%		75.68	%		75.01	%
	Risk free interest rate	2.44	%		1.53	%		1.26	%
	Dividend yield	—			—			—
	Term (years)	9.68			7.68			8.28
	The following table presents the weighted-average assumptions used to estimate the fair value of options granted to employees during the periods presented:
		Year Ended December 31,
		2014				2013				2012
	Volatility	70.17		%		76.6		%		77.39		%
	Risk free interest rate	1.78		%		1.79		%		1.43		%
	Dividend yield	—				—				—
	Term (years)	5.98				6.14				6.5
	Weighted-average fair value of options granted during the period	$	5.29			$	9.85			$	23.35
Nonvested Restricted Stock Shares Activity	The following table summarizes the activities for our non-vested restricted stock awards for the years ended December 31, 2014 and 2013:
				Non-vested Restricted Stock Awards
				Number of Shares				Weighted-Average Grant Date Fair Value
	Non-vested at January 1, 2013			$	—			$	—
	Granted			7,500				13.5
	Vested			(2,500		)		15.39
	Non-vested at December 31, 2013			$	5,000			$	12.55
	Granted			220,000				9.01
	Vested			(80,000		)		10.19
	Forfeited/canceled			(12,500		)		12.04
	Non-vested at December 31, 2014			$	132,500			$	8.14
Effects of Stock-Based Compensation Related to Stock Option and Restricted Stock Awards	The following table presents the effects of stock-based compensation related to stock option and restricted stock awards to employees and non-employees on our Statement of Operations during the periods presented:
		Year Ended December 31,
		2014				2013				2012
	Cost of revenues	$	148,852			$	41,470			$	11,753
	Research and development	472,573				114,189				460,321
	General and administrative	3,058,465				516,127				297,175
	Sales and marketing	155,459				63,359				146,112
	Total stock-based compensation	$	3,835,349			$	735,145			$	915,361

Warrants_Tables

Warrants (Tables)	12 Months Ended
	Dec. 31, 2014
Warrants and Rights Note Disclosure [Abstract]
Summary of Warrant Activity	The following table summarizes the warrant activity for the years ending December 31, 2014, 2013 and 2012:
	Issued With / For		Exercise		Warrants	2012	2012		2012		2012		Warrants	2013	2013		2013		IPO		Warrants	2014		2014		Warrants
			Price		Outstanding	Warrants	Warrants		Warrants		Warrants		Outstanding	Warrants	Warrants		Warrants		Adjustments		Outstanding	Warrants		Warrants		Outstanding
					January 1,	Issued	Exercised		Surrendered		Expired		December 31,	Issued	Exercised		Expired		(E)		December 31,	Exercised		Expired		December 31,
					2012								2012								2013					2014
	Non-Derivative Warrants:
	Financing		$	10	—	—	—		—		—		—	—	—		—		243,334		243,334	—		—		243,334
	Financing		14.1		8,865	—	(2,482	)	—		(6,383	)	—	—	—		—		—		—	—		—		—
	Financing		15		—	—	—		—		—		—	—	—		—		436,079		436,079	—		—		436,079
	Debt Guarantee		4		228,288	—	—		—		—		228,288	—	(54,000	)	—		—		174,288	(174,288	)	—		—
	Debt Guarantee		10		—	—	—		—		—		—	—	—		—		237,500		237,500	—		(237,500	)	—
	Debt Guarantee		15		—	—	—		—		—		—	—	—		—		585,645		585,645	—		(233,333	)	352,312
	Series A Pref. Stock		10.75		30,000	—	(30,000	)	—		—		—	—	—		—		—		—	—		—		—
	Series A Pref. Stock		14.1		89,214	—	(18,616	)	—		(5,269	)	65,329	—	(29,868	)	(35,461	)	—		—	—		—		—
	Consulting		10		—	—	—		—		—		—	—	—		—		29,138		29,138	—		—		29,138
			13.72 F		356,367	—	(51,098	)	—		(11,652	)	293,617	—	(83,868	)	(35,461	)	1,531,696		1,705,984	(174,288	)	(470,833	)	1,060,863
	Derivative Warrants:
	Series A Pref. Stock		4.00 A		7,325	—	(3,812	)	—		(3,513	)	—	—	—		—		—		—	—		—		—
	Financing		10.00 B		—	—	—		—		—		—	—	—		—		60,000		60,000	—		—		60,000
	Financing		25.00 B		60,000	—	—		—		—		60,000	—	—		—		(60,000	)	—	—		—		—
	Financing		42.50 BCD		42,353	189,117	—		(156,176	)	—		75,294	—	—		—		(75,294	)	—	—		—		—
	Financing		42.50 AD		—	54,314	—		—		—		54,314	2,941	—		—		(57,255	)	—	—		—		—
	Financing		42.50 ACD		—	120,865	—		—		—		120,865	6,471	—		—		(127,336	)	—	—		—		—
	Debt Guarantee		10.00 A		—	—	—		—		—		—	—	—		—		12,500		12,500	(12,500	)	—		—
	Debt Guarantee		25.00 ACD		212,000	—	—		—		—		212,000	—	—		—		(212,000	)	—	—		—		—
	Debt Guarantee		25.00 AD		100,000	—	—		—		—		100,000	—	—		—		(100,000	)	—	—		—		—
	Debt Guarantee		32.45 AC		40,000	—	—		—		—		40,000	—	—		—		(40,000	)	—	—		—		—
	Debt Guarantee		42.50 ACD		—	75,392	—		(37,000	)	—		38,392	—	—		—		(38,392	)	—	—		—		—
	Debt Guarantee		42.50 BCD		—	37,000	—		—		—		37,000	—	—		—		(37,000	)	—	—		—		—
	Series B Pref. Stock		10.00 B		—	—	—		—		—		—	—	(34,034	)	—		52,464		18,430	(3,415	)	—		15,015
	Series B Pref. Stock		25.00 B		52,464	—	—		—		—		52,464	—	—		—		(52,464	)	—	—		—		—
	Consulting		10.00 B		—	—	—		—		—		—	—	—		—		200		200	—		—		200
	Consulting		12.50 AD		4,030	—	—		—		—		4,030	—	—		—		(4,030	)	—	—		—		—
	Consulting		14.10 AD		10,000	—	—		—		—		10,000	—	—		—		(10,000	)	—	—		—		—
	Consulting		25.00 BD		200	—	—		—		—		200	—	—		—		(200	)	—	—		—		—
	Consulting		25.00 AD		4,000	—	—		—		—		4,000	—	—		—		(4,000	)	—	—		—		—
			10.00 F		532,372	476,688	(3,812	)	(193,176	)	(3,513	)	808,559	9,412	(34,034	)	—		(692,807	)	91,130	(15,915	)	—		75,215
			13.47 F		888,739	476,688	(54,910	)	(193,176	)	(15,165	)	1,102,176	9,412	(117,902	)	(35,461	)	838,889		1,797,114	(190,203	)	(470,833	)	1,136,078
	_________________________
	A	These warrants are subject to fair value accounting and contain exercise price and number of share adjustment features. See Note 13.
	B	These warrants are subject to fair value accounting and contain an exercise price adjustment feature. See Note 13.
	C	On February 11, 2013, these warrants held by John Pappajohn were amended to limit the adjustment feature(s) to $15.00 per share in an initial public offering (totaling 530,022 warrants).
	D	The exercise price and/or number of share adjustment features of these warrants expired and are no longer subject to fair value accounting after our initial public offering.
	E	On April 10, 2013 the Company completed the IPO at $10.00 per share. The shares of common stock issuable upon the exercise of warrants outstanding as of April 10, 2013 increased by 838,889 shares and the exercise prices of 1,656,860 warrants were adjusted as a result of the share and exercise price adjustment features described above.
	F	Weighted average exercise prices are as of December 31, 2014.

Fair_Value_of_Warrants_Tables

Fair Value of Warrants (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Assumptions Used in Computing Fair Value of Derivative Warrants	The following tables summarize the assumptions used in computing the fair value of derivative warrants subject to fair value accounting at the date of issue during the years ended December 31, 2014, 2013 and 2012 and at December 31, 2014, December 31, 2013 and April 5, 2013 (IPO valuation date). In computing the fair value of the warrants, if the stated exercise price of the warrants exceeded the assumed value of the Company stock at the date the fair value was being computed, the exercise price and number of shares (if applicable) underlying the warrants were adjusted to reflect an assumed trigger of the price and/or share adjustment features related to the applicable warrants. Such adjustments were only applicable to 2012 and 2013 due to the relative price of the warrants and the assumed Company stock price:
	Debt Guarantee	Exercised During the year ended December 31, 2014			Issued During the year ended December 31, 2012			As of December 31, 2013			IPO Date
											April 5, 2013
	Exercise Price	$	10		$	9.6		$	10		$	13.56
	Expected life (years)	0.6			4.66			0.83			2.42
	Expected volatility	49.01		%	80.05		%	57.33		%	66.37		%
	Risk-free interest rate	0.08		%	0.82		%	0.13		%	0.32		%
	Expected dividend yield	0		%	0		%	0		%	0		%
	Series B	Exercised During the Year Ended December 31, 2014			As of December 31,
					2014			2013
	Exercise Price	$	10		$	10		$	10
	Expected life (years)	1.72			0.88			1.92
	Expected volatility	46.6		%	49.95		%	59.26		%
	Risk-free interest rate	0.33		%	0.25		%	0.38		%
	Expected dividend yield	0		%	0		%	0		%
		As of December 31,						IPO Date
	Consulting	2014			2013			April 5, 2013
	Exercise Price	$	10		$	10		$	10
	Expected life (years)	1.14			2.14			2.33
	Expected volatility	49.25		%	62.63		%	63.2		%
	Risk-free interest rate	0.25		%	0.38		%	0.27		%
	Expected dividend yield	0		%	0		%	0		%
		Issued During						As of December 31,						IPO Date
		the Year Ended												April 5,
		December 31,
	Financing	2014			2013			2014			2013			2013
	Exercise Price	$	—		$	13.34		$	10		$	10		$	13.21
	Expected life (years)	0			9.78			1.23			2.25			8.3
	Expected volatility	—		%	74.7		%	50.23		%	64.4		%	73.22		%
	Risk-free interest rate	—		%	1.95		%	0.25		%	0.38		%	1.44		%
	Expected dividend yield	0		%	0		%	0		%	0		%	0		%
Summary of Derivative Warrant Activity	The following table summarizes the derivative warrant activity subject to fair value accounting for the years ended December 31, 2014, 2013 and 2012:
		Issued with			Issued with			Issued For			Issued For			Issued For			Total
		Series A			Series B			Debt			Consulting			Financing
		Preferred			Preferred			Guarantee
		Stock			Stock
	Fair value of warrants outstanding as of January 1, 2012	$	220,000		$	1,160,000		$	6,993,000		$	447,000		$	2,293,000		$	11,113,000
	Fair value of warrants issued	—			—			1,583,000			—			4,961,000			6,544,000
	Fair value of warrants exercised	(55,000		)	—			—			—			—			(55,000		)
	Warrant restructuring	—			—			268,000			—			2,217,000			2,485,000
	Change in fair value of warrants	(165,000		)	(930,000		)	(3,165,000		)	(300,000		)	(2,978,000		)	(7,538,000		)
	Fair value of warrants outstanding as of December 31, 2012	—			230,000			5,679,000			147,000			6,493,000			12,549,000
	Fair value of warrants issued	—			—			—			—			268,000			268,000
	Fair value of warrants exercised	—			(420,000		)	—			—			—			(420,000		)
	Reclassification to equity in IPO	—			—			(2,514,000		)	(108,000		)	(4,548,000		)	(7,170,000		)
	Change in fair value of warrants	—			307,000			(3,101,000		)	(38,000		)	(1,801,000		)	(4,633,000		)
	Fair value of warrants outstanding as of December 31, 2013	—			117,000			64,000			1,000			412,000			594,000
	Fair value of warrants exercised	—			(38,000		)	(87,000		)	—			—			(125,000		)
	Change in fair value of warrants	—			(71,000		)	23,000			(1,000		)	(368,000		)	(417,000		)
	Fair value of warrants outstanding as of December 31, 2014	$	—		$	8,000		$	—		$	—		$	44,000		$	52,000

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Summary of Financial Liabilities Measured at Fair Value on Recurring Basis	The following table summarizes the financial liabilities measured at fair value on a recurring basis segregated by the level of valuation inputs within the fair value hierarchy utilized to measure fair value:
		2014
		Total			Quoted Prices in		Significant Other	Significant
					Active Markets for		Observable	Unobservable
					Identical Assets		Inputs	Inputs
					(Level 1)		(Level 2)	(Level 3)
	Warrant liability	$	52,000		—		—	$	52,000
	Gentris contingent consideration	293,400			—		—	293,400
	Notes payable to VenturEast	534,828			—		—	534,828
		$	880,228		—		—	$	880,228
		2013
		Total			Quoted Prices in		Significant Other	Significant
					Active Markets for		Observable	Unobservable
					Identical Assets		Inputs	Inputs
					(Level 1)		(Level 2)	(Level 3)
	Warrant liability	$	594,000		—		—	$	594,000
Schedule of Fair Value Notes Payable for Contingent Consideration of Business Acquisitions	The following table summarizes the activity of the notes payable to VenturEast and Gentris contingent consideration which were measured at fair value using Level 3 inputs:
		Note Payable			Gentris Contingent
		to VenturEast			Consideration
	Fair value at January 1, 2014	$	—		$	—
	Fair value at issuance	733,387			293,400
	Change in fair value	(198,559		)	—
	Fair value at December 31, 2014	$	534,828		$	293,400

Organization_Acquisitions_Desc2

Organization, Acquisitions, Description of Business, Reverse Stock Split and Charter Amendment - Additional Information (Detail) (USD $)	0 Months Ended					4 Months Ended	6 Months Ended	12 Months Ended			0 Months Ended		9 Months Ended
	Aug. 18, 2014	Oct. 28, 2013	Apr. 10, 2013	Mar. 01, 2013	Feb. 08, 2013	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Aug. 19, 2013	Jul. 16, 2014	Sep. 30, 2014	Oct. 31, 2013	Sep. 05, 2013
	agreement
Business Acquisition [Line Items]
Number of agreements	2
Change in fair value of acquisition note payable								($198,000)	$0	$0
Business Acquisition, Pro Forma Information [Abstract]
Pro forma revenue of acquiree since acquisition date							3,296,465
Pro forma earnings (loss) of acquiree since acquisition date						-1,438,118
Reverse stock split ratio				0.4	0.5
Public Offerings [Abstract]
Common stock, shares issued		3,286,700	690,000			9,821,169	9,821,169	9,821,169	9,275,384					10,000
Public offering price per share (in dollars per share)		$14	$10
Gross proceeds from public offering		46,000,000	6,900,000
Net proceeds from initial public offering		42,300,000						0	61,516,994	0
Aggregate number of Series A and Series B convertible preferred stock converted into common stock			1,287,325
Reclassification of derivative warrants			7,200,000					0	7,170,000	0
Value of debt converted			9,634,300					0	9,634,300	0
Conversion of debt into common stock			963,430
Underwriter's overallotment shares		428,700	90,000
IPO
Public Offerings [Abstract]
Common stock, shares issued			690,000
Public offering price per share (in dollars per share)			$10
Gross proceeds from public offering			6,900,000
Net proceeds from initial public offering			5,000,000
Secondary Offering
Public Offerings [Abstract]
Common stock, shares issued											1,500,000
Public offering price per share (in dollars per share)											$10
Gross proceeds from public offering											15,000,000
Net proceeds from secondary public offering											13,300,000
Amount used for repayment of certain indebtedness											3,500,000
Additional common stock sold at public offering															105,000
Additional gross proceeds from issuance of shares															1,100,000
Additional net proceeds from issuance of shares															947,000
Gentris Corporation
Business Acquisition [Line Items]
Acquisition related costs												147,500
Maximum period to complete final valuation								12 months
Bio Serve Biotechnologies India Private Limited
Business Acquisition [Line Items]
Maximum period to complete final valuation													12 months
Agreement One
Business Acquisition [Line Items]
Aggregate ownership percentage	74.00%
Agreement Two
Business Acquisition [Line Items]
Aggregate ownership percentage	15.00%
Ventureast Trustee Company Pvt Ltd | Bio Serve Biotechnologies India Private Limited
Business Acquisition [Line Items]
Business combination, consideration transferred, notes payable in shares	84,278
Maximum period for payment	30 months
Change in fair value of acquisition note payable								198,000
Contingent Consideration for Revenues of $4.75 million | Gentris Corporation
Business Acquisition [Line Items]
Contingent consideration												4,750,000
Contingent Consideration for Revenues of $8.55 million | Gentris Corporation
Business Acquisition [Line Items]
Contingent consideration												8,550,000
Patents
Business Acquisition [Line Items]
Accumulated amortization of patents						84,000	84,000	84,000	56,000
Public Offerings [Abstract]
2015						34,900	34,900	34,900
2019						31,600	31,600	31,600
Thereafter						$93,400	$93,400	$93,400

Organization_Acquisitions_Desc3

Organization, Acquisitions, Description of Business, Reverse Stock Split and Charter Amendment - Gentris Acquisition (Details) (USD $)	12 Months Ended			0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 16, 2014
Business Acquisition [Line Items]
Value of shares issued as partial consideration to purchase Gentris and BioServe	$1,515,992	$0	$0
Gentris Corporation
Business Acquisition [Line Items]
Cash paid at closing				3,250,000
Value of shares issued as partial consideration to purchase Gentris and BioServe				1,271,745
Consideration liabilities incurred				293,400
Total Purchase Price				$4,815,145
Common Stock | Gentris Corporation
Business Acquisition [Line Items]
Equity interest number of shares				147,843

Organization_Acquisitions_Desc4

Organization, Acquisitions, Description of Business, Reverse Stock Split and Charter Amendment - Gentris Liabilities & Assets Assumed (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Jul. 16, 2014
Business Acquisition [Line Items]
Goodwill	$2,994,135	$0
Gentris Corporation
Business Acquisition [Line Items]
Accounts receivable			1,869,097
Other current assets			265,612
Current liabilities			-785,246
Deferred revenue, long-term			-937,773
Fixed Assets			1,950,885
Goodwill			2,452,570
Total Purchase Price			$4,815,145

Organization_Acquisitions_Desc5

Organization, Acquisitions, Description of Business, Reverse Stock Split and Charter Amendment - BioServe Acquisition (Details) (USD $)	12 Months Ended			0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Aug. 18, 2014
Business Acquisition [Line Items]
Value of shares issued as partial consideration to purchase Gentris and BioServe	$1,515,992	$0	$0
Bio Serve Biotechnologies India Private Limited
Business Acquisition [Line Items]
Cash paid at closing				72,907
Consideration liabilities incurred				23,708
Value of shares issued as partial consideration to purchase Gentris and BioServe				244,247
Total Purchase Price				1,074,249
Ventureast Trustee Company Pvt Ltd | Bio Serve Biotechnologies India Private Limited
Business Acquisition [Line Items]
Consideration liabilities incurred				$733,387
Minimum | Bio Serve Biotechnologies India Private Limited
Business Acquisition [Line Items]
Debt Instrument, Term				12 months
Maximum | Bio Serve Biotechnologies India Private Limited
Business Acquisition [Line Items]
Debt Instrument, Term				18 months
Common Stock | Bio Serve Biotechnologies India Private Limited
Business Acquisition [Line Items]
Equity interest number of shares				31,370,000,000

Organization_Acquisitions_Desc6

Organization, Acquisitions, Description of Business, Reverse Stock Split and Charter Amendment - BioServe Liabilities & Assets Assumed (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Aug. 18, 2014
Business Acquisition [Line Items]
Goodwill	$2,994,135	$0
Bio Serve Biotechnologies India Private Limited
Business Acquisition [Line Items]
Accounts receivable			151,002
Other current assets			120,528
Fixed Assets			624,948
Other assets			416,869
Goodwill			541,565
Current liabilities			-758,614
Other liabilities			-22,049
Total Purchase Price			$1,074,249

Organization_Acquisitions_Desc7

Organization, Acquisitions, Description of Business, Reverse Stock Split and Charter Amendment - Proforma (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Business Acquisition, Pro Forma Information [Abstract]
Revenue	$14,365,402	$15,767,519	$12,528,553
Net loss	($18,498,333)	($13,677,432)	($7,918,262)
Basic net loss per share (in dollars per share)	($1.94)	($2.82)	($5.20)
Dilutive net loss per share (in dollars per share)	($1.98)	($3.77)	($10.13)

Significant_Accounting_Policie3

Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	Segment
Significant Accounting Policies [Line Items]
Number of operating segment	1
Unrecognized tax benefits, income tax penalties and interest expense	$0	$0	$0
Uncertain tax positions	0
Accrual for interest or penalties	0	0	0
Intangible asset impairments	0	0	0
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Accrued liability related to registration rights obligations associated with the issuance of Series B preferred stock and certain notes payable	300,000	300,000
Loss in equity-method investment	939,913	12,343	0
Other Assets [Member]
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Net receivable due from the joint venture	10,000	24,000
Patents
Significant Accounting Policies [Line Items]
Accumulated amortization of patents	84,000	56,000
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2015	34,900
2016	34,900
2017	34,900
2018	34,900
2019	31,600
Thereafter	93,400
Research and development
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Loss in equity-method investment	940,000	12,000
Minimum
Significant Accounting Policies [Line Items]
Fixed assets, estimated useful lives	5 years
Maximum
Significant Accounting Policies [Line Items]
Fixed assets, estimated useful lives	7 years
Wells Fargo Bank | Restricted Cash [Member]
Significant Accounting Policies [Line Items]
Line of credit	6,000,000
Letter of Credit [Member] | Restricted Cash [Member]
Significant Accounting Policies [Line Items]
Line of credit	$300,000

Significant_Accounting_Policie4

Significant Accounting Policies - Computation of Basic Net Income (Loss) and Diluted Net Loss per Share Data (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Numerator:
Net loss	($16,642,919)	($12,372,553)	($6,665,627)
Change in fair value of warrant liability	417,000	4,633,000	7,538,000
Net (loss) for diluted earnings per share	($17,059,919)	($17,005,553)	($14,203,627)
Denominator:
Weighted-average basic common shares outstanding (in shares)	9,449,189	4,665,316	1,342,174
Assumed conversion of dilutive securities:
Common stock purchase warrants	12,474	10,658	3,987
Potentially dilutive common shares	12,474	10,658	3,987
Denominator for diluted earnings per share-adjusted weighted-average shares (in shares)	9,461,663	4,675,974	1,346,161
Basic net income (loss) per share (usd per share)	($1.76)	($2.65)	($4.97)
Diluted net loss per share (usd per share)	($1.80)	($3.64)	($10.55)

Significant_Accounting_Policie5

Significant Accounting Policies - Summary of Potentially Dilutive Adjustments to Weighted Average Number of Common Shares Excluded from Calculation (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation	3,032,821	2,583,026	2,372,450
Series A Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation	0	0	352,614
Series B Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation	0	0	364,320
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation	1,060,863	1,701,984	1,102,176
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation	1,839,458	873,542	553,340
Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation	132,500	7,500	0

Significant_Accounting_Policie6

Significant Accounting Policies - Schedule of Goodwill (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Goodwill [Roll Forward]
Balance, December 31, 2013	$0
Purchased through acquisitions	2,994,135
Balance, December 31, 2014	$2,994,135

Revenue_and_Accounts_Receivabl2

Revenue and Accounts Receivable - Schedule of Revenue by Payor Type (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$10,199,387	$6,609,957	$4,301,563
Biopharma Services
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	5,605,780	2,650,285	578,505
Clinical Services
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	4,432,272	3,662,795	3,166,118
Discovery Services
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	161,335	0	0
Grants
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$0	$296,877	$556,940

Revenue_and_Accounts_Receivabl3

Revenue and Accounts Receivable - Schedule of Accounts Receivable by Payor Type (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for doubtful accounts	($251,176)	($36,000)	($36,000)
Accounts receivable, net	5,028,620	1,567,039
Biopharma Services
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	3,203,335	428,341
Clinical Services
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	1,925,176	1,174,698
Discovery Services
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$151,285	$0

Revenue_and_Accounts_Receivabl4

Revenue and Accounts Receivable Revenue and Accounts Receivable - Schedule of Product Information (Details) (Payor, Sales Revenue, Net)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Product Information [Line Items]
Percentage of revenue	43.00%	55.00%	74.00%
Medicare
Product Information [Line Items]
Percentage of revenue	11.00%	13.00%	18.00%
Other insurers
Product Information [Line Items]
Percentage of revenue	16.00%	25.00%	32.00%
Other healthcare facilities
Product Information [Line Items]
Percentage of revenue	16.00%	18.00%	24.00%

Revenue_and_Accounts_Receivabl5

Revenue and Accounts Receivable - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	client	client	client
Accounts, Notes, Loans and Financing Receivable [Line Items]
Sites accounted for approximately 10% or more of our revenue	2	1	3
Biopharma Services | Payor | Sales | 10% or More Clinical Revenue
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of revenue		40.00%	13.00%
University Teaching Center | Payor | Sales | 10% or More Clinical Revenue
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of revenue			11.00%
Community Hospital | Payor | Sales | 10% or More Clinical Revenue
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of revenue			10.00%
Customer One | Biopharma Services | Payor | Sales | 10% or More Clinical Revenue
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of revenue	23.00%
Customer Two | Biopharma Services | Payor | Sales | 10% or More Clinical Revenue
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of revenue	12.00%
Clinical Testing | Payor | Testing Volume
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of revenue	56.00%	69.00%	58.00%
Community Hospitals | Payor | Testing Volume
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of revenue	38.00%	36.00%	46.00%

Revenue_and_Accounts_Receivabl6

Revenue and Accounts Receivable - Schedule of Allowance for Doubtful Accounts (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Allowance for Doubtful Accounts Receivable [Roll Forward]
Beginning of the period	$36,000	$36,000
Additions to Allowance for doubtful accounts	215,176	0	-4,597
Deductions to Allowance for doubtful accounts	0	0
End of the period	$251,176	$36,000	$36,000

Other_Current_Assets_Schedule_

Other Current Assets - Schedule of Other Current Assets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Inventory probes	$279,894	$198,789
Prepaid expenses	911,320	593,950
Grants receivable	0	71,877
Other assets, current	$1,191,214	$864,616

Lease_Commitments_Additional_I

Lease Commitments - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Lease Disclosure [Line Items]
Lease agreement expiration date	28-Feb-18
Security deposit for lease	$300,000
Equipment under these capital leases, cost	395,687
Equipment under these capital leases, accumulated depreciation	29,936
Rent expense	$692,324	$550,882	$516,173
Minimum
Lease Disclosure [Line Items]
Periodic rent increases per square foot per year	1
Maximum
Lease Disclosure [Line Items]
Periodic rent increases per square foot per year	2
Rutherford, New Jersey Office and Laboratory Space
Lease Disclosure [Line Items]
Operating leases, office space area	17,900
Morrisville, North Carolina Office and Laboratory Space
Lease Disclosure [Line Items]
Operating leases, office space area	24,900
Hyderabad, India Office and Laboratory Space
Lease Disclosure [Line Items]
Operating leases, office space area	10,000
Shanghai, China Office and Laboratory Space
Lease Disclosure [Line Items]
Operating leases, office space area	2,700

Lease_Commitments_Minimum_Futu

Lease Commitments - Minimum Future Lease Payments Under All Capital and Operating Leases (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Schedule Of Operating And Capital Leased Assets [Line Items]
2015	$928,475
2016	937,237
2017	932,032
2018	419,234
2019	379,979
Thereafter	218,875
Total minimum lease payments	3,815,832
Obligations under capital leases, current portion	58,950	51,400
Obligations under capital leases	300,385	309,777
Capital Leases [Member]
Schedule Of Operating And Capital Leased Assets [Line Items]
2015	74,280
2016	74,280
2017	61,625
2018	59,094
2019	59,094
Thereafter	83,800
Total minimum lease payments	412,173
Less amount representing interest	52,838
Present value of net minimum obligations	359,335
Obligations under capital leases, current portion	58,950
Obligations under capital leases	300,385
Operating Leases [Member]
Schedule Of Operating And Capital Leased Assets [Line Items]
2015	854,195
2016	862,957
2017	870,407
2018	360,140
2019	320,885
Thereafter	135,075
Total minimum lease payments	$3,403,659

Notes_Payable_and_Lines_of_Cre2

Notes Payable and Lines of Credit - Additional Information (Detail) (USD $)	0 Months Ended		12 Months Ended			1 Months Ended	0 Months Ended
	Aug. 19, 2013	Apr. 10, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Oct. 31, 2012	Feb. 22, 2013	Mar. 07, 2013	Dec. 07, 2012
Debt Instrument [Line Items]
Debt instrument spread on variable rate	6.25%
Remaining debt discount after conversion		$3,500,000
Accrued fee on debt instrument		419,000
Recognizable conversion feature in converted debt		3,000,000
Conversion of outstanding debt to common stock		9,634,300	0	9,634,300	0
Common shares		963,430
Outstanding balance, repaid	1,500,000
Line of credit outstanding under credit agreement			6,000,000	0
IPO or merger price		$10
2012 Convertible Debt Financing Transaction
Debt Instrument [Line Items]
Conversion of outstanding debt to common stock						1,000,000
Conversion price of loan into common stock						20.00%
IPO or merger price						$53.12
Warrant exercise price discount on IPO or merger price						20.00%
IPO or merger price						$53.13
NNJCA
Debt Instrument [Line Items]
Conversion of outstanding debt to common stock		500,000
Common shares		50,000
NNJCA | IPO
Debt Instrument [Line Items]
Conversion price of notes		$10
Wells Fargo Bank
Debt Instrument [Line Items]
Borrowings from utilization of line of credit			6,000,000	6,000,000
Debt instrument maturity date			1-Apr-16
Debt instrument spread on variable rate			1.75%
Interest on line of credit at end period			1.91%
Restricted cash required as collateral			6,000,000
December 2011 Financing Transaction
Debt Instrument [Line Items]
Conversion of outstanding debt to common stock		4,500,000
Common shares		450,000
December 2011 Financing Transaction | IPO
Debt Instrument [Line Items]
Conversion price of notes		$10
December 2011 Financing Transaction | John Pappajohn
Debt Instrument [Line Items]
Debt outstanding under credit agreement		4,000,000
Conversion of outstanding debt to common stock		4,000,000
December 2011 Financing Transaction | NNJCA
Debt Instrument [Line Items]
Debt outstanding under credit agreement		1,500,000
Conversion of outstanding debt to common stock		500,000
Common shares		450,000
December 2011 Financing Transaction | Dr. Pecora
Debt Instrument [Line Items]
Debt outstanding under credit agreement		500,000
2012 Convertible Debt Financing Transaction
Debt Instrument [Line Items]
Debt outstanding under credit agreement		3,000,000
Conversion of outstanding debt to common stock		3,000,000
Common shares		300,000
IPO or merger price							$10
2012 Convertible Debt Financing Transaction | IPO
Debt Instrument [Line Items]
Conversion price of notes		$10
2012 Convertible Debt Financing Transaction | John Pappajohn
Debt Instrument [Line Items]
Debt outstanding under credit agreement		1,750,000
2012 Convertible Debt Financing Transaction | Mr. Mark Oman
Debt Instrument [Line Items]
Debt outstanding under credit agreement		1,250,000
December 2012 Bridge Financing Transaction
Debt Instrument [Line Items]
Conversion of outstanding debt to common stock		1,000,000
Common shares		100,000							100,000
IPO or merger price								$10
December 2012 Bridge Financing Transaction | IPO
Debt Instrument [Line Items]
Conversion price of notes									10
December 2012 Bridge Financing Transaction | John Pappajohn
Debt Instrument [Line Items]
Debt outstanding under credit agreement									1,000,000
Business Lines of Credit (DAM)
Debt Instrument [Line Items]
Conversion of outstanding debt to common stock		1,000,000
Common shares		100,000
Line of credit, indebtedness		1,000,000
Line of credit, repaid	2,000,000
Business Lines of Credit (DAM) | IPO
Debt Instrument [Line Items]
Conversion price of notes		$10
Other Note Payable
Debt Instrument [Line Items]
Common shares		13,430
Conversion price of notes		$10
Notes payable, Long-Term		$100,000

Notes_Payable_and_Lines_of_Cre3

Notes Payable and Lines of Credit - Summary of Short-Term and Long-Term Debt Obligations (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Notes Payable, Current Portion	$0	$22,298
Line of credit	0	6,000,000
Lines of Credit, Long-Term	6,000,000	0
Secured Note Payable
Debt Instrument [Line Items]
Notes Payable, Current Portion	$0	$22,298

Notes_Payable_and_Lines_of_Cre4

Notes Payable and Lines of Credit - Conversion of Indebtedness into Shares of Common Stock (Detail) (USD $)	0 Months Ended	12 Months Ended			0 Months Ended
	Apr. 10, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 07, 2012
Debt Conversion [Line Items]
Converted Amount	$9,634,300	$0	$9,634,300	$0
Common shares	963,430
December 2011 Financing Transaction
Debt Conversion [Line Items]
Converted Amount	4,500,000
Common shares	450,000
2012 Convertible Debt Financing Transaction
Debt Conversion [Line Items]
Converted Amount	3,000,000
Common shares	300,000
December 2012 Bridge Financing Transaction
Debt Conversion [Line Items]
Converted Amount	1,000,000
Common shares	100,000				100,000
Business Lines of Credit (DAM)
Debt Conversion [Line Items]
Converted Amount	1,000,000
Common shares	100,000
Other Notes Payable and Accrued Interest [Member]
Debt Conversion [Line Items]
Converted Amount	$134,300
Common shares	13,430

Notes_Payable_and_Lines_of_Cre5

Notes Payable and Lines of Credit - Loss on Debt and Warrant Restructuring (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Debt Instrument [Line Items]
Loss (Gain) on debt and warrant restructuring	$0	$0	$1,862,012
Settlement | Line of Credit
Debt Instrument [Line Items]
Loss (Gain) on debt and warrant restructuring			-129,500
Settlement | 2011 Convertible Debt Financing Transaction
Debt Instrument [Line Items]
Loss (Gain) on debt and warrant restructuring			-328,000
Amendment | Line of Credit
Debt Instrument [Line Items]
Loss (Gain) on debt and warrant restructuring			268,000
Amendment | 2011 Convertible Debt Financing Transaction
Debt Instrument [Line Items]
Loss (Gain) on debt and warrant restructuring			545,000
Restated | 2012 Convertible Debt Financing Transaction
Debt Instrument [Line Items]
Loss (Gain) on debt and warrant restructuring			$1,506,512

Letter_of_Credit_Additional_In

Letter of Credit - Additional Information (Detail) (USD $)	Dec. 31, 2014
Debt Disclosure [Abstract]
Stand-by letter of credit	$300,000

Fixed_Assets_Fixed_Assets_Summ

Fixed Assets - Fixed Assets Summary by Major Classifications (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Equipment	$5,913,928	$2,513,066
Furniture and fixtures	548,093	461,119
Leasehold improvements	869,578	595,689
Gross	7,331,599	3,569,874
Less accumulated depreciation	-2,885,006	-2,305,250
Net fixed assets	$4,446,593	$1,264,624

Income_Taxes_Income_Tax_Reconc

Income Taxes - Income Tax Reconciliation (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Income tax benefit at federal statutory rate	($6,648,000)	($4,563,000)	($2,333,000)
State tax provision, net of federal tax benefit	-807,000	-359,000	-661,000
Tax credits	-154,000	-126,000	-82,000
Stock based compensation permanent differences	207,000	229,000	85,000
Derivative warrant permanent differences	-146,000	-1,622,000	-1,926,000
Investor consideration permanent differences	-69,000	0	0
Debt and warrant conversion costs permanent difference	0	3,454,000	0
Change in valuation allowance	5,255,000	2,356,000	4,858,000
Other	12,000	-33,000	59,000
Income tax (benefit) provision	($2,350,185)	($663,900)	$0
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Income tax benefit at federal statutory rate	35.00%	35.00%	35.00%
State tax provision, net of federal tax benefit	4.20%	2.80%	9.50%
Tax credits	0.80%	1.00%	1.10%
Stock based compensation permanent differences	-1.10%	-1.80%	-1.20%
Derivative warrant permanent differences	0.80%	12.40%	26.00%
Investor consideration permanent differences	0.40%	0.00%	0.00%
Debt and warrant conversion costs permanent difference	0.00%	-26.50%	0.00%
Change in valuation allowance	-27.70%	-18.10%	-70.20%
Other	0.00%	0.30%	-0.20%
Income tax (benefit) provision	12.40%	5.10%	0.00%

Income_Taxes_Components_of_App

Income Taxes - Components of Approximate Deferred Tax (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred tax assets:
Net operating loss carryforwards	$20,982	$17,140
Accruals and reserves	773	509
Non-qualified stock options	1,912	877
Research and development tax credits	758	603
Derivative warrant liability	26	26
Investment in joint venture	163	163
Goodwill	23	0
Other	6	5
Total deferred tax assets	24,643	19,323
Less valuation allowance	-24,558	-19,303
Net deferred tax assets	85	20
Deferred tax liabilities
Fixed assets	-85	-20
Net deferred taxes	$0	$0

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax [Line Items]
Income tax (benefit) provision	($2,350,185)	($663,900)	$0
Domestic Tax Authority [Member]
Income Tax [Line Items]
Net operating loss carryforward	57,000,000
NEW JERSEY
Income Tax [Line Items]
Net operating loss carryforward	28,640,223	8,018,107
Proceeds from sale of operating loss carryforward	$2,350,185	$663,900

Capital_Stock_Additional_Infor

Capital Stock - Additional Information (Detail) (USD $)	0 Months Ended
	Oct. 28, 2013	Apr. 10, 2013	Aug. 19, 2013	Dec. 31, 2014	Dec. 31, 2013	Oct. 31, 2013	Sep. 05, 2013
Class of Stock [Line Items]
Common stock, shares issued	3,286,700	690,000		9,821,169	9,275,384	10,000
Underwriter's overallotment shares	428,700	90,000
Common stock sold at IPO, price per share	$14	$10
Gross proceeds from public offering	$46,000,000	$6,900,000
Number of shares converted to common stock		1,287,325
Preferred stock, shares authorized				9,764,000
Secondary Offering
Class of Stock [Line Items]
Common stock, shares issued			1,500,000
Common stock sold at IPO, price per share			$10
Gross proceeds from public offering			15,000,000
Net proceeds from secondary public offering			13,300,000
Additional common stock sold at public offering							105,000
Gross proceeds from issuance of shares							1,100,000
Additional net proceeds from issuance of shares							947,000
Follow-On Offering [Member]
Class of Stock [Line Items]
Common stock, shares issued	3,286,700
Underwriter's overallotment shares	428,700
Common stock sold at IPO, price per share	$14
Gross proceeds from public offering	46,000,000
Net proceeds from secondary public offering	$42,300,000
Series A Preferred Stock
Class of Stock [Line Items]
Number of shares converted to common stock		376,525
Preferred stock, shares authorized					588,000
Series B Preferred Stock
Class of Stock [Line Items]
Number of shares converted to common stock		910,800
Preferred stock, shares authorized					2,000,000
Cleveland Clinic [Member]
Class of Stock [Line Items]
Common stock, shares issued		2,000

Stock_Option_Plans_Additional_

Stock Option Plans - Additional Information (Detail) (USD $)

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Apr. 10, 2013

Apr. 05, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Oct. 31, 2013

Apr. 30, 2013

Dec. 31, 2010

31-May-14

Dec. 31, 2011

22-May-14

Jun. 30, 2011

Apr. 01, 2010

Apr. 29, 2008

Stock_Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Options granted maximum exercisable period

10 years

Number of equity incentive plans

2

Issuance of shares under stock options plans

48,000

Stock appreciation rights

0

Restricted stock awarded under Stock Option Plans

227,500

Outstanding stock options

336,300

1,839,458

Initial public offering exercisable lower price range

$12.50

Initial public offering exercisable upper price range

$33.80

Initial offering, options exchanged

242,070

Exercise price option

$10

Approved options issued

53,500

Fair value of common stock

$6.68

$13.78

$9.60

Stock options exercise price

$10

Price per share on equity offering

$10

Proceeds from option exercises

$79,018

$1,640

$0

Stock options exercised, intrinsic value

120,510

1,630

Options exchanged

30,083

164

Number of shares outstanding

1,839,458

873,542

553,340

559,990

Employee stock option purchased

1,154,800

426,762

2,400

Non-Employee

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Issuance of shares under stock options plans

80,000

Stock options strike price

$25

$25

Unrecognized compensation cost

645,739

94,359

Unrecognized compensation cost, period for recognition

2 years 11 months 12 days

1 year 9 months 11 days

Options exchanged

48,000

10,000

Exercise price of options exchanged

$10

$15.39

Option Holder

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Options forfeitures in period

11,429

Options net shares issued

571

Options exchanged

12,000

Employee

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Unrecognized compensation cost

6,058,774

Unrecognized compensation cost, period for recognition

3 years 8 months 12 days

Director

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Issuance of shares under stock options plans

200,000

Exercise price of options exchanged

$15.89

2011 Equity Incentive Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares of common stock reserved for issuance

350,000

Number of common stock shares authorized for issuance

2,000,000

Shares available for future awards

386,044

2008 Stock Option Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares of common stock reserved for issuance

550,000

251,475

Shares available for future awards

89,051

Restricted Stock

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Compensation cost not yet recognized, equity instruments other than options

852,206

Unrecognized compensation cost, period for recognition

3 years

Restricted Stock | Non-Employee

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Compensation cost not yet recognized, equity instruments other than options

$12,948

Unrecognized compensation cost, period for recognition

9 months 11 days

Strike Price of $25.00 or More

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exchange options for number of options held with exercise price equal to initial public offering price, Percentage

60.00%

Price per share on equity offering

$10

Strike Price of $12.50

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock options strike price

$12.50

Exchange options for number of options held with exercise price equal to initial public offering price, Percentage

80.00%

Price per share on equity offering

$10

Stock_Option_Plans_Summary_of_

Stock Option Plans - Summary of Employee and Nonemployee Stock Option Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Options Outstanding, Number of Shares Outstanding
Outstanding, beginning balance	873,542	553,340	559,990
Granted	1,154,800	426,762	2,400
Exercised	-30,083	-164
Cancelled or expired	-158,801	-106,396	-9,050
Outstanding, ending balance	1,839,458	873,542	553,340	559,990
Exercisable	635,435
Options Outstanding, Weighted Average Exercise Price
Outstanding, beginning balance	$10.83	$12.76	$12.85
Granted	$10.41	$14.57	$33.80
Exercised	$6.61	$10
Cancelled or expired	$11.45	$20.46	$23.43
Outstanding, ending balance	$10.58	$10.83	$12.76	$12.85
Exercisable	$9.14
Weighted-Average Remaining Contractual Term (in years)
Outstanding	8 years 5 months 26 days	7 years 9 months	7 years 1 month 17 days	8 years 1 month 6 days
Exercisable	6 years 8 months 19 days
Aggregate Intrinsic Value
Outstanding, beginning balance	$3,138,539	$1,142,432	$11,737,710
Outstanding, ending balance	618,250	3,138,539	1,142,432	11,737,710
Exercisable	$478,219

Stock_Option_Plans_Summary_of_1

Stock Option Plans - Summary of Outstanding and Vested Stock Options Granted (Detail) (USD $)	0 Months Ended	12 Months Ended
	Apr. 05, 2013	Dec. 31, 2014	Apr. 05, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price lower range limit	$12.50
Exercise price upper range limit	$33.80
Number of Shares, Options Outstanding	336,300	1,839,458	336,300
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)		8 years 5 months 27 days
Weighted-Average Exercise Price, Options Outstanding (usd per share)		$10.58
Number of Shares Options Vested and Exercisable		635,435
Weighted-Average Exercise Price, Options Vested and Exercisable (usd per share)		$9.14
Exercise Price 4.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price lower range limit		$4,000,000
Exercise price upper range limit		$4,000,000
Number of Shares, Options Outstanding		145,000
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)		4 years 2 months 19 days
Weighted-Average Exercise Price, Options Outstanding (usd per share)		$4
Number of Shares Options Vested and Exercisable		145,000
Weighted-Average Exercise Price, Options Vested and Exercisable (usd per share)		$4
Exercise Price 4.80
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price lower range limit		$4,800,000
Exercise price upper range limit		$4,800,000
Number of Shares, Options Outstanding		30,914
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)		5 years 18 days
Weighted-Average Exercise Price, Options Outstanding (usd per share)		$4.80
Number of Shares Options Vested and Exercisable		30,432
Weighted-Average Exercise Price, Options Vested and Exercisable (usd per share)		$4.80
Exercise Price 6.30
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price lower range limit		$6,300,000
Exercise price upper range limit		$6,300,000
Number of Shares, Options Outstanding		451,400
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)		9 years 11 months 12 days
Weighted-Average Exercise Price, Options Outstanding (usd per share)		$6.30
Number of Shares Options Vested and Exercisable		85,280
Weighted-Average Exercise Price, Options Vested and Exercisable (usd per share)		$6.30
Exercise Price 7.44
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price lower range limit		$7,440,000
Exercise price upper range limit		$7,440,000
Number of Shares, Options Outstanding		7,500
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)		9 years 11 months 23 days
Weighted-Average Exercise Price, Options Outstanding (usd per share)		$7.44
Number of Shares Options Vested and Exercisable		0
Weighted-Average Exercise Price, Options Vested and Exercisable (usd per share)		$0
Exercise Price 9.09
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price lower range limit		$9,090,000
Exercise price upper range limit		$9,090,000
Number of Shares, Options Outstanding		223,400
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)		9 years 8 months 27 days
Weighted-Average Exercise Price, Options Outstanding (usd per share)		$9.09
Number of Shares Options Vested and Exercisable		20,681
Weighted-Average Exercise Price, Options Vested and Exercisable (usd per share)		$9.09
Exercise Price 10.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price lower range limit		$10,000,000
Exercise price upper range limit		$10,000,000
Number of Shares, Options Outstanding		230,788
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)		5 years 7 months 24 days
Weighted-Average Exercise Price, Options Outstanding (usd per share)		$10
Number of Shares Options Vested and Exercisable		209,395
Weighted-Average Exercise Price, Options Vested and Exercisable (usd per share)		$10
Exercise Price 11.70 - 11.75
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price lower range limit		$11,700,000
Exercise price upper range limit		$11,750,000
Number of Shares, Options Outstanding		50,400
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)		9 years 3 months 18 days
Weighted-Average Exercise Price, Options Outstanding (usd per share)		$11.70
Number of Shares Options Vested and Exercisable		2,066
Weighted-Average Exercise Price, Options Vested and Exercisable (usd per share)		$11.74
Exercise Price 12.50 - 14.18
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price lower range limit		$12,500,000
Exercise price upper range limit		$14,180,000
Number of Shares, Options Outstanding		105,700
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)		9 years 4 days
Weighted-Average Exercise Price, Options Outstanding (usd per share)		$13.99
Number of Shares Options Vested and Exercisable		1,351
Weighted-Average Exercise Price, Options Vested and Exercisable (usd per share)		$13.98
Exercise Price 15.39
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price lower range limit		$15,390,000
Exercise price upper range limit		$15,390,000
Number of Shares, Options Outstanding		304,356
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)		8 years 9 months 11 days
Weighted-Average Exercise Price, Options Outstanding (usd per share)		$15.39
Number of Shares Options Vested and Exercisable		90,230
Weighted-Average Exercise Price, Options Vested and Exercisable (usd per share)		$15.39
Exercise Price 15.89
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price lower range limit		$15,890,000
Exercise price upper range limit		$15,890,000
Number of Shares, Options Outstanding		200,000
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)		9 years 4 months 24 days
Weighted-Average Exercise Price, Options Outstanding (usd per share)		$15.89
Number of Shares Options Vested and Exercisable		37,500
Weighted-Average Exercise Price, Options Vested and Exercisable (usd per share)		$15.89
Exercise Price 17.38
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price lower range limit		$17,380,000
Exercise price upper range limit		$17,380,000
Number of Shares, Options Outstanding		90,000
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)		9 years 2 months 19 days
Weighted-Average Exercise Price, Options Outstanding (usd per share)		$17.38
Number of Shares Options Vested and Exercisable		13,500
Weighted-Average Exercise Price, Options Vested and Exercisable (usd per share)		$17.38

Stock_Option_Plans_WeightedAve

Stock Option Plans - Weighted-Average Assumptions Used to Estimate Fair Value of Options Granted (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Non-Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	71.76%	75.68%	75.01%
Risk free interest rate	2.44%	1.53%	1.26%
Dividend yield	0.00%	0.00%	0.00%
Term (years)	9 years 8 months 5 days	7 years 8 months 5 days	8 years 3 months 11 days
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	70.17%	76.60%	77.39%
Risk free interest rate	1.78%	1.79%	1.43%
Dividend yield	0.00%	0.00%	0.00%
Term (years)	5 years 11 months 23 days	6 years 1 month 21 days	6 years 6 months
Weighted-average fair value of options granted during the period	5.29	9.85	23.35

Stock_Option_Plans_Summary_of_2

Stock Option Plans - Summary of Restricted Stock Award Activity (Details) (Restricted Stock, USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Restricted Stock
Number of Shares (in shares):
Restricted stock outstanding beginning of period	5,000	0
Granted	220,000	7,500
Vested	-80,000	-2,500
Forfeited/canceled	-12,500
Restricted stock outstanding end of period	132,500	5,000
Weighted-Average Grant Date Fair Value (in dollars per share):
Restricted stock outstanding beginning of period	$12.55	$0
Granted, weighted average grant date fair value	$9.01	$13.50
Vested, weighted average grant date fair value	$10.19	$15.39
Forfeited/canceled, weighted average grant date fair value	$12.04
Restricted stock outstanding end of period	$8.14	$12.55

Stock_Option_Plans_Effects_of_

Stock Option Plans - Effects of Stock-Based Compensation Related to Stock Option and Restricted Stock Awards (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	$3,835,349	$735,145	$915,361
Cost of revenues
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	148,852	41,470	11,753
Research and development
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	472,573	114,189	460,321
General and administrative
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	3,058,465	516,127	297,175
Sales and marketing
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	$155,459	$63,359	$146,112

Warrants_Detail

Warrants (Detail) (USD $)	0 Months Ended											1 Months Ended						12 Months Ended			1 Months Ended		0 Months Ended		1 Months Ended		0 Months Ended	1 Months Ended
	Oct. 08, 2013	Oct. 07, 2013	Sep. 30, 2013	Sep. 27, 2013	Sep. 10, 2013	Jul. 08, 2013	Jul. 06, 2013	Apr. 29, 2013	Apr. 10, 2013	Sep. 27, 2012	Aug. 14, 2012	Jul. 31, 2014	Jun. 30, 2014	Mar. 31, 2014	Feb. 28, 2014	Jan. 31, 2014	Feb. 29, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2012	Mar. 31, 2011	Feb. 22, 2013	Mar. 07, 2013	Oct. 31, 2012	Dec. 31, 2011	Oct. 22, 2012	Oct. 31, 2014	Sep. 06, 2012	Feb. 11, 2013
Class of Warrant or Right [Line Items]
Warrants granted											4,706						28,235
Fair value of warrants at the date of issue										$144,000
Warrants issued to a consultant for services provided																		200
Warrants to purchase common stock, issued										65,328																			70,598
Warrants exercise price																		$13.47
Warrants surrendered	23,188	23,188	14,313				2,072					45,894		7,230	1,661					193,176
Warrants, lock-up agreement period										180 days
Warrants exercised, shares																		190,203	117,902	54,910
Warrants exercised, value																				690,227
Warrants, expired																				15,164
Price per share on equity offering									$10
Shares issuable on exercise of warrants									838,889										838,889
Number of warrants effected with adjusted exercise price									1,656,860
Proceeds form warrants exercised						96,000		96,000					177,154			950		178,102	192,000	635,227
Warrants exercised to purchase common stock	33,868	33,868	30,034			24,000	6,000	24,000				130,000	44,288	12,500	1,659	95
Common stock per share value on warrant exercised			$10			$4	$4	$4				$4	$4	$10	$10	$10
Warrants Issued	10,680	10,680	15,721				3,928					84,106		5,270	3,320				9,412	476,688
Warrant outstanding				42,468	42,468													1,136,078	1,797,114	1,102,176						888,739
Extended expiration date of warrant				11 days	17 days
Maximum
Class of Warrant or Right [Line Items]
Common stock per share value on warrant exercised	14.1	14.1
Minimum
Class of Warrant or Right [Line Items]
Common stock per share value on warrant exercised	10	10
Line of Credit
Class of Warrant or Right [Line Items]
Warrants granted																					15,000	60,000
Fair value of warrants at the date of issue																					306,000	1,019,000
2012 Convertible Debt Financing Transaction
Class of Warrant or Right [Line Items]
Fair value of warrants at the date of issue																							221,000
Warrants exercise price																							$15
Term of warrants																							10 years
Price per share on equity offering																							$10
December 2012 Bridge Financing Transaction
Class of Warrant or Right [Line Items]
Warrants granted																								2,353
Fair value of warrants at the date of issue																		47,000
Term of warrants																								10 years
Price per share on equity offering																								$10
Financing Arrangements
Class of Warrant or Right [Line Items]
Warrants granted																									20,669	112,940
Fair value of warrants at the date of issue																				1,522,000					606,000	951,000
Warrants surrendered																									37,646
Warrants amended																									75,294
John Pappajohn
Class of Warrant or Right [Line Items]
Fair value of warrants at the date of issue																											298,000
Warrants to purchase common stock, issued																											10,157
Final IPO price to determine exercise price of the warrants																								$15
Adjusted exercise price of warrants on initial public offerings																														$15
John Pappajohn | Maximum
Class of Warrant or Right [Line Items]
Warrants exercise price																											$42.50
John Pappajohn | Debt Guarantee
Class of Warrant or Right [Line Items]
Warrants granted																		1,051,506
Fair value of warrants at the date of issue																		0	0	1,555,000						831,000
John Pappajohn | Bridge Loan
Class of Warrant or Right [Line Items]
Warrants granted																				23,529
Fair value of warrants at the date of issue																				837,000
John Pappajohn | 2012 Convertible Debt Financing Transaction
Class of Warrant or Right [Line Items]
Warrants granted																							4,118
John Pappajohn | Financing Arrangements
Class of Warrant or Right [Line Items]
Warrants granted																									9,412
Fair value of warrants at the date of issue																									267,000
Mr. Mark Oman | 2012 Convertible Debt Financing Transaction
Class of Warrant or Right [Line Items]
Warrants granted																							2,941
Certain Warrant Holders
Class of Warrant or Right [Line Items]
Warrants to purchase common stock, issued																														114,030
Mr.Pappajohn
Class of Warrant or Right [Line Items]
Warrants granted																		4,000
Fair value of warrants at the date of issue																		69,000
Related Parties | 2012 Convertible Debt Financing Transaction
Class of Warrant or Right [Line Items]
Warrants granted																				28,235					114,510
Fair value of warrants at the date of issue																		$1,107,000							$4,090,000
Financial Guarantee
Class of Warrant or Right [Line Items]
Class of warrant or right, expired																												470,833
Warrants exercised, shares																		440,113
Financial Guarantee | John Pappajohn
Class of Warrant or Right [Line Items]
Class of warrant or right, expired																		233,333										233,333
Non-Derivative Warrants | Warrant Issued With
Class of Warrant or Right [Line Items]
Warrants exercise price																		$13.72
Warrants exercised, shares																		174,288	83,868	51,098
Shares issuable on exercise of warrants																			1,531,696
Warrant outstanding																		1,060,863	1,705,984	293,617						356,367
Derivative Warrants | Warrant Issued For
Class of Warrant or Right [Line Items]
Warrants exercise price																		$10
Warrants surrendered																				193,176
Warrants exercised, shares																		15,915	34,034	3,812
Shares issuable on exercise of warrants																			-692,807
Warrants Issued																			9,412	476,688
Warrant outstanding																		75,215	91,130	808,559						532,372
Derivative Warrants | Warrant Issued For | Consulting
Class of Warrant or Right [Line Items]
Warrants exercise price																		$25
Shares issuable on exercise of warrants																			-4,000
Warrant outstanding																				4,000						4,000
Derivative Warrants | Warrant Issued For | Consulting
Class of Warrant or Right [Line Items]
Warrants exercise price																		$25
Shares issuable on exercise of warrants																			-200
Warrant outstanding																				200						200
Derivative Warrants | Warrant Issued For | Consulting
Class of Warrant or Right [Line Items]
Warrants exercise price																		$14.10
Shares issuable on exercise of warrants																			-10,000
Warrant outstanding																				10,000						10,000
Derivative Warrants | Warrant Issued For | Consulting
Class of Warrant or Right [Line Items]
Warrants exercise price																		$12.50
Shares issuable on exercise of warrants																			-4,030
Warrant outstanding																				4,030						4,030
Derivative Warrants | Warrant Issued For | Consulting
Class of Warrant or Right [Line Items]
Warrants exercise price																		$10
Shares issuable on exercise of warrants																			200
Warrant outstanding																		200	200
Derivative Warrants | Warrant Issued For | Financing
Class of Warrant or Right [Line Items]
Warrants exercise price																		$42.50
Shares issuable on exercise of warrants																			-127,336
Warrants Issued																			6,471	120,865
Warrant outstanding																				120,865
Derivative Warrants | Warrant Issued For | Financing
Class of Warrant or Right [Line Items]
Warrants exercise price																		$42.50
Shares issuable on exercise of warrants																			-57,255
Warrants Issued																			2,941	54,314
Warrant outstanding																				54,314
Derivative Warrants | Warrant Issued For | Financing
Class of Warrant or Right [Line Items]
Warrants exercise price																		$42.50
Warrants surrendered																				156,176
Shares issuable on exercise of warrants																			-75,294
Warrants Issued																				189,117
Warrant outstanding																				75,294						42,353
Derivative Warrants | Warrant Issued For | Financing
Class of Warrant or Right [Line Items]
Warrants exercise price																		$25
Shares issuable on exercise of warrants																			-60,000
Warrant outstanding																				60,000						60,000
Derivative Warrants | Warrant Issued For | Financing
Class of Warrant or Right [Line Items]
Warrants exercise price																		$10
Shares issuable on exercise of warrants																			60,000
Warrant outstanding																		60,000	60,000
Derivative Warrants | Warrant Issued For | Debt Guarantee
Class of Warrant or Right [Line Items]
Warrants exercise price																		$10
Warrants exercised, shares																		12,500
Shares issuable on exercise of warrants																			12,500
Warrant outstanding																			12,500
Derivative Warrants | Warrant Issued For | Debt Guarantee
Class of Warrant or Right [Line Items]
Warrants exercise price																		$25
Shares issuable on exercise of warrants																			-212,000
Warrant outstanding																				212,000						212,000
Derivative Warrants | Warrant Issued For | Debt Guarantee
Class of Warrant or Right [Line Items]
Warrants exercise price																		$25
Shares issuable on exercise of warrants																			-100,000
Warrant outstanding																				100,000						100,000
Derivative Warrants | Warrant Issued For | Debt Guarantee
Class of Warrant or Right [Line Items]
Warrants exercise price																		$32.45
Shares issuable on exercise of warrants																			-40,000
Warrant outstanding																				40,000						40,000
Derivative Warrants | Warrant Issued For | Debt Guarantee
Class of Warrant or Right [Line Items]
Warrants exercise price																		$42.50
Warrants surrendered																				37,000
Shares issuable on exercise of warrants																			-38,392
Warrants Issued																				75,392
Warrant outstanding																				38,392
Derivative Warrants | Warrant Issued For | Debt Guarantee
Class of Warrant or Right [Line Items]
Warrants exercise price																		$42.50
Shares issuable on exercise of warrants																			-37,000
Warrants Issued																				37,000
Warrant outstanding																				37,000
Derivative Warrants | Warrant Issued For | Debt Guarantee
Class of Warrant or Right [Line Items]
Warrants exercise price																		$25
Derivative Warrants | Series A Preferred Stock | Warrant Issued For
Class of Warrant or Right [Line Items]
Warrants exercise price																		$4
Warrants exercised, shares																				3,812
Warrant outstanding																										7,325

Warrants_Summary_of_Warrant_Ac

Warrants - Summary of Warrant Activity (Detail) (USD $)	0 Months Ended					1 Months Ended			12 Months Ended
	Oct. 08, 2013	Oct. 07, 2013	Sep. 30, 2013	Jul. 06, 2013	Apr. 10, 2013	Jul. 31, 2014	Mar. 31, 2014	Feb. 28, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 27, 2013	Sep. 10, 2013	Dec. 31, 2011	Feb. 11, 2013
Class of Warrant or Right [Line Items]
Warrants exercise price									$13.47
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance									1,797,114	1,102,176	888,739	42,468	42,468
Warrants Issued	10,680	10,680	15,721	3,928		84,106	5,270	3,320		9,412	476,688
Warrants Exercised									-190,203	-117,902	-54,910
Warrants Surrendered	-23,188	-23,188	-14,313	-2,072		-45,894	-7,230	-1,661			-193,176
Warrants Expired									-470,833	-35,461	-15,165
IPO Adjustments					838,889					838,889
Warrants Outstanding, Ending Balance									1,136,078	1,797,114	1,102,176	42,468	42,468
Common stock issued upon closing initial public offering fair value Per Share					$10
Common shares issuable upon exercise of warrants or rights					838,889
Number of warrants effected with adjusted exercise price					1,656,860
Warrant Issued With | Non-Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$13.72
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance									1,705,984	293,617	356,367
Warrants Exercised									-174,288	-83,868	-51,098
Warrants Expired									-470,833	-35,461	-11,652
IPO Adjustments										1,531,696
Warrants Outstanding, Ending Balance									1,060,863	1,705,984	293,617
Warrant Issued For | Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$10
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance									91,130	808,559	532,372
Warrants Issued										9,412	476,688
Warrants Exercised									-15,915	-34,034	-3,812
Warrants Surrendered											-193,176
Warrants Expired											-3,513
IPO Adjustments										-692,807
Warrants Outstanding, Ending Balance									75,215	91,130	808,559
Debt Guarantee | Warrant Issued With | Non-Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$4
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance									174,288	228,288				228,288
Warrants Exercised									-174,288	-54,000
Warrants Outstanding, Ending Balance										174,288				228,288
Debt Guarantee | Warrant Issued With | Non-Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$10
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance									237,500
Warrants Expired									-237,500
IPO Adjustments										237,500
Debt Guarantee | Warrant Issued With | Non-Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$15
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance									585,645
Warrants Expired									-233,333
IPO Adjustments										585,645
Warrants Outstanding, Ending Balance									352,312
Debt Guarantee | Warrant Issued For | Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$10
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance									12,500
Warrants Exercised									-12,500
IPO Adjustments										12,500
Debt Guarantee | Warrant Issued For | Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$25
Debt Guarantee | Warrant Issued For | Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$25
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance														212,000
IPO Adjustments										-212,000
Warrants Outstanding, Ending Balance											212,000			212,000
Debt Guarantee | Warrant Issued For | Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$25
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance														100,000
IPO Adjustments										-100,000
Warrants Outstanding, Ending Balance											100,000			100,000
Debt Guarantee | Warrant Issued For | Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$32.45
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance														40,000
IPO Adjustments										-40,000
Warrants Outstanding, Ending Balance											40,000			40,000
Debt Guarantee | Warrant Issued For | Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$42.50
Class of Warrants Outstanding [Roll Forward]
Warrants Issued											75,392
Warrants Surrendered											-37,000
IPO Adjustments										-38,392
Warrants Outstanding, Ending Balance											38,392
Debt Guarantee | Warrant Issued For | Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$42.50
Class of Warrants Outstanding [Roll Forward]
Warrants Issued											37,000
IPO Adjustments										-37,000
Warrants Outstanding, Ending Balance											37,000
Series A Preferred Stock | Warrant Issued For | Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$4
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance											7,325
Warrants Exercised											-3,812
Warrants Expired											-3,513
Series A Preferred Stock | Instrument Type One | Warrant Issued With | Non-Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$10.75
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance											30,000
Warrants Exercised											-30,000
Series A Preferred Stock | Instrument Type Two | Warrant Issued With | Non-Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$14.10
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance										65,329	89,214
Warrants Exercised										-29,868	-18,616
Warrants Expired										-35,461	-5,269
Warrants Outstanding, Ending Balance											65,329
Series B Preferred Stock | Instrument Type One | Warrant Issued For | Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$10
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance									18,430
Warrants Exercised									-3,415	-34,034
IPO Adjustments										52,464
Warrants Outstanding, Ending Balance									15,015	18,430
Series B Preferred Stock | Instrument Type Two | Warrant Issued For | Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$25
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance														52,464
IPO Adjustments										-52,464
Warrants Outstanding, Ending Balance											52,464			52,464
Financing | Warrant Issued With | Non-Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$10
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance									243,334
IPO Adjustments										243,334
Warrants Outstanding, Ending Balance									243,334
Financing | Warrant Issued With | Non-Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$14.10
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance											8,865
Warrants Exercised											-2,482
Warrants Expired											-6,383
Financing | Warrant Issued With | Non-Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$15
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance									436,079
IPO Adjustments										436,079
Warrants Outstanding, Ending Balance									436,079
Consulting | Warrant Issued With | Non-Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$10
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance									29,138
IPO Adjustments										29,138
Warrants Outstanding, Ending Balance									29,138
Financing | Warrant Issued For | Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$10
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance									60,000
IPO Adjustments										60,000
Warrants Outstanding, Ending Balance									60,000
Financing | Warrant Issued For | Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$25
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance														60,000
IPO Adjustments										-60,000
Warrants Outstanding, Ending Balance											60,000			60,000
Financing | Warrant Issued For | Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$42.50
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance											42,353
Warrants Issued											189,117
Warrants Surrendered											-156,176
IPO Adjustments										-75,294
Warrants Outstanding, Ending Balance											75,294
Financing | Warrant Issued For | Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$42.50
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance										54,314
Warrants Issued										2,941	54,314
IPO Adjustments										-57,255
Warrants Outstanding, Ending Balance											54,314
Financing | Warrant Issued For | Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$42.50
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance										120,865
Warrants Issued										6,471	120,865
IPO Adjustments										-127,336
Warrants Outstanding, Ending Balance											120,865
Consulting | Warrant Issued For | Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$10
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance									200
IPO Adjustments										200
Warrants Outstanding, Ending Balance									200
Consulting | Warrant Issued For | Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$12.50
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance														4,030
IPO Adjustments										-4,030
Warrants Outstanding, Ending Balance											4,030			4,030
Consulting | Warrant Issued For | Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$14.10
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance														10,000
IPO Adjustments										-10,000
Warrants Outstanding, Ending Balance											10,000			10,000
Consulting | Warrant Issued For | Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$25
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance														200
IPO Adjustments										-200
Warrants Outstanding, Ending Balance											200			200
Consulting | Warrant Issued For | Derivative Warrants
Class of Warrant or Right [Line Items]
Warrants exercise price									$25
Class of Warrants Outstanding [Roll Forward]
Warrants Outstanding, Beginning Balance														4,000
IPO Adjustments										-4,000
Warrants Outstanding, Ending Balance											4,000			4,000
IPO
Class of Warrants Outstanding [Roll Forward]
Share price of warrants issued to related party adjustment for initial public offering															$15
Class of warrant issued															530,022

Fair_Value_of_Warrants_Assumpt

Fair Value of Warrants - Assumptions Used in Computing Fair Value of Derivative Warrants (Detail) (USD $)	0 Months Ended		12 Months Ended	0 Months Ended	12 Months Ended	1 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Apr. 05, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013
Series B Preferred Stock
Class of Warrant or Right [Line Items]
Exercise Price	$10	$10	$10
Expected life (years)	10 months 17 days	1 year 11 months 1 day	1 year 8 months 19 days
Expected volatility	49.95%	59.26%	46.60%
Risk-free interest rate	0.25%	0.38%	0.33%
Expected dividend yield	0.00%	0.00%	0.00%
Debt Guarantee
Class of Warrant or Right [Line Items]
Exercise Price		$10	$10	$13.56	$9.60
Expected life (years)		9 months 29 days	7 months 6 days	2 years 5 months 1 day	4 years 7 months 28 days
Expected volatility		57.33%	49.01%	66.37%	80.05%
Risk-free interest rate		0.13%	0.08%	0.32%	0.82%
Expected dividend yield		0.00%	0.00%	0.00%	0.00%
Financing
Class of Warrant or Right [Line Items]
Exercise Price	$10		$0	$13.21		$10	$13.34
Expected life (years)	1 year 2 months 23 days		0 years	8 years 3 months 18 days		2 years 3 months	9 years 9 months 11 days
Expected volatility	50.23%		0.00%	73.22%		64.40%	74.70%
Risk-free interest rate	0.25%		0.00%	1.44%		0.38%	1.95%
Expected dividend yield	0.00%		0.00%	0.00%		0.00%	0.00%
Consulting
Class of Warrant or Right [Line Items]
Exercise Price	$10	$10		$10
Expected life (years)	1 year 1 month 21 days	2 years 1 month 21 days		2 years 3 months 29 days
Expected volatility	49.25%	62.63%		63.20%
Risk-free interest rate	0.25%	0.38%		0.27%
Expected dividend yield	0.00%	0.00%		0.00%

Fair_Value_of_Warrants_Additio

Fair Value of Warrants - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Class of Warrant or Right [Line Items]
Fair value of warrants issue price	$6.68	$13.78	$9.60
Minimum
Class of Warrant or Right [Line Items]
Fair value of stock prices in computing fair value for warrants issued	$6.68	$9.60	$9.60
Maximum
Class of Warrant or Right [Line Items]
Fair value of stock prices in computing fair value for warrants issued	$19.86	$20.26	$33.80

Fair_Value_of_Warrants_Summary

Fair Value of Warrants - Summary of Derivative Warrant Activity (Detail) (USD $)	0 Months Ended	12 Months Ended
	Apr. 10, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Class of Warrants Outstanding [Roll Forward]
Beginning balance		$594,000	$12,549,000	$11,113,000
Fair value of warrants issued			268,000	6,544,000
Fair value of warrants exercised		-125,000	-420,000	-55,000
Warrant restructuring				2,485,000
Reclassification to equity in IPO	-7,200,000	0	-7,170,000	0
Change in fair value of warrants		-417,000	-4,633,000	-7,538,000
Ending balance		52,000	594,000	12,549,000
Debt Guarantee
Class of Warrants Outstanding [Roll Forward]
Beginning balance		64,000	5,679,000	6,993,000
Fair value of warrants issued				1,583,000
Fair value of warrants exercised		-87,000
Warrant restructuring				268,000
Reclassification to equity in IPO			-2,514,000
Change in fair value of warrants		23,000	-3,101,000	-3,165,000
Ending balance			64,000	5,679,000
Consulting
Class of Warrants Outstanding [Roll Forward]
Beginning balance		1,000	147,000	447,000
Reclassification to equity in IPO			-108,000
Change in fair value of warrants		-1,000	-38,000	-300,000
Ending balance			1,000	147,000
Financing
Class of Warrants Outstanding [Roll Forward]
Beginning balance		412,000	6,493,000	2,293,000
Fair value of warrants issued			268,000	4,961,000
Warrant restructuring				2,217,000
Reclassification to equity in IPO			-4,548,000
Change in fair value of warrants		-368,000	-1,801,000	-2,978,000
Ending balance		44,000	412,000	6,493,000
Series A Preferred Stock
Class of Warrants Outstanding [Roll Forward]
Beginning balance				220,000
Fair value of warrants exercised				-55,000
Change in fair value of warrants				-165,000
Series B Preferred Stock
Class of Warrants Outstanding [Roll Forward]
Beginning balance		117,000	230,000	1,160,000
Fair value of warrants exercised		-38,000	-420,000
Change in fair value of warrants		-71,000	307,000	-930,000
Ending balance		$8,000	$117,000	$230,000

Fair_Value_Measurements_Summar

Fair Value Measurements - Summary of Financial Liabilities Measured at Fair Value on Recurring Basis (Detail) (Recurring, USD $)	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$52,000	$594,000
Total liabilities	880,228
Gentris Corporation
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	293,400
Bio Serve Biotechnologies India Private Limited
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	534,828
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	0	0
Total liabilities	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Gentris Corporation
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Bio Serve Biotechnologies India Private Limited
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	0	0
Total liabilities	0
Significant Other Observable Inputs (Level 2) | Gentris Corporation
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0
Significant Other Observable Inputs (Level 2) | Bio Serve Biotechnologies India Private Limited
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	52,000	594,000
Total liabilities	880,228
Significant Unobservable Inputs (Level 3) | Gentris Corporation
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	293,400
Significant Unobservable Inputs (Level 3) | Bio Serve Biotechnologies India Private Limited
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	$534,828

Fair_Value_Measurements_Summar1

Fair Value Measurements - Summary of Fair Value of Notes Payable (Details) (Recurring, Significant Unobservable Inputs (Level 3), Contingent Consideration Liability, USD $)	12 Months Ended
	Dec. 31, 2014
Bio Serve Biotechnologies India Private Limited
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value beginning balance	$0
Fair value at issuance	733,387
Change in fair value	-198,559
Fair value ending balance	534,828
Gentris Corporation
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value beginning balance	0
Fair value at issuance	293,400
Change in fair value	0
Fair value ending balance	$293,400

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Details) (USD $)	12 Months Ended			0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Aug. 18, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in fair value of acquisition note payable	($198,000)	$0	$0
Bio Serve Biotechnologies India Private Limited | Ventureast Trustee Company Pvt Ltd
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination, consideration transferred, notes payable in shares				84,278
Change in fair value of acquisition note payable	$198,000

Joint_Venture_Agreement_Detail

Joint Venture Agreement (Detail) (USD $)	1 Months Ended	3 Months Ended	12 Months Ended			3 Months Ended
	Oct. 31, 2013	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2014	Jun. 30, 2015	Oct. 28, 2013	Apr. 10, 2013
Schedule of Equity Method Investments [Line Items]
Capital contribution in exchange of membership interests			$1,000,000	$1,000,000	$0
Common stock, shares issued	10,000	9,275,384	9,821,169	9,275,384				3,286,700	690,000
Additional expense related to shares issued	175,000	231,000
Joint Venture Agreement
Schedule of Equity Method Investments [Line Items]
Percentage of outstanding membership interests in joint venture			50.00%
Capital contribution in exchange of membership interests	1,000,000					1,000,000
Fair value of capital contribution in joint venture			6,000,000
Joint Venture Agreement | Forecast
Schedule of Equity Method Investments [Line Items]
Capital contribution in exchange of membership interests							1,000,000
Joint Venture Agreement | Maximum
Schedule of Equity Method Investments [Line Items]
Capital contribution in exchange of membership interests			$4,000,000

Related_Party_Transactions_Det

Related Party Transactions (Detail) (USD $)

0 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

Oct. 08, 2013

Oct. 07, 2013

Sep. 30, 2013

Aug. 19, 2013

Jul. 06, 2013

Apr. 10, 2013

Aug. 14, 2012

Sep. 15, 2010

Jul. 31, 2014

Mar. 31, 2014

Feb. 28, 2014

Feb. 29, 2012

Mar. 31, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Oct. 31, 2014

Dec. 21, 2011

Aug. 15, 2010

Oct. 15, 2012

Jan. 06, 2014

Apr. 01, 2014

Aug. 31, 2010

19-May-06

Feb. 28, 2015

Oct. 31, 2013

Oct. 28, 2013

extension

patent

Related Party Transaction [Line Items]

Number of revolving line of credit extensions facility

8

Common stock exercised

190,203

117,902

54,910

Convertible shares issued to common stock

690,000

9,821,169

9,275,384

10,000

3,286,700

Conversion of outstanding indebtedness to common stock

$9,634,300

$0

$9,634,300

$0

Common shares

963,430

Debt instrument spread on variable rate

6.25%

Interest rate at period end

9.50%

Pre-payment penalty paid

130,000

Debt instrument amount paid upon conversion of the notes

32,667

Consulting agreement period

3 years

Stock option issued to related party, price per share (usd per share)

$10.41

$14.57

$33.80

Warrants issued

4,706

28,235

Number of warrants agreed to be surrendered

23,188

23,188

14,313

2,072

45,894

7,230

1,661

193,176

Employee stock option purchased

1,154,800

426,762

2,400

Financial Guarantee

Related Party Transaction [Line Items]

Common stock purchased

284,000

284,000

Common stock exercised

440,113

Class of warrant or right, expired

470,833

IPO

Related Party Transaction [Line Items]

Convertible shares issued to common stock

690,000

John Pappajohn

Related Party Transaction [Line Items]

Common stock purchased

202,630

Warrants adjusted in conjunction with IPO

436,079

Warrants outstanding per share

$15

Additional amount of loan received

6,750,000

John Pappajohn | Financial Guarantee

Related Party Transaction [Line Items]

Common stock purchased

1,051,506

1,051,506

Class of warrant or right, expired

233,333

233,333

Warrants adjusted in conjunction with IPO

352,312

Warrants outstanding per share

$15

John Pappajohn | IPO

Related Party Transaction [Line Items]

Convertible shares issued to common stock

675,000

Conversion price of notes

$10

NNJCA

Related Party Transaction [Line Items]

Additional amount of loan received

1,500,000

Conversion of outstanding indebtedness to common stock

500,000

Common shares

50,000

NNJCA | IPO

Related Party Transaction [Line Items]

Conversion price of notes

$10

Dr. Pecora

Related Party Transaction [Line Items]

Additional amount of loan received

500,000

Consulting agreement period

2 years

Agreement with related party, fee

5,000

Stock option issued to related party

12,000

Stock option issued to related party, price per share (usd per share)

$25

Dr. Pecora | Expensed under Stock Option Plan

Related Party Transaction [Line Items]

Agreement with related party, consulting fee

0

0

142,740

Pecora and NNJCA

Related Party Transaction [Line Items]

Number of warrants agreed to be surrendered

37,646

Increase the pre-payment penalties

130,000

Board of Directors Chairman

Related Party Transaction [Line Items]

Compensation for serving as chairman of the board, annual amount

100,000

Board of Directors Chairman | 2011 Equity Plan

Related Party Transaction [Line Items]

Employee stock option purchased

100,000

Equity Dynamics, Inc.

Related Party Transaction [Line Items]

Agreement with related party, consulting fee

120,000

120,000

120,000

Related party consulting fees

10,000

10,000

Dr. Chaganti

Related Party Transaction [Line Items]

Notes issued to related party

100,000

Interest rate due to related party

8.50%

Interest expenses on notes issued to related party

2,400

8,400

Agreement with related party, fee

5,000

Agreement with related party, consulting fee

60,000

60,000

60,000

Convertible number of common shares

13,430

Common stock issued upon conversion (usd per share)

$10

Dr. Chaganti | 2011 Equity Plan

Related Party Transaction [Line Items]

Common stock, vesting period

4 years

Common stock, shares purchased price per share (usd per share)

$15.89

Employee stock option purchased

200,000

Restricted Stock

Related Party Transaction [Line Items]

Equity instruments granted in period

220,000

7,500

Restricted Stock | Board of Directors Chairman

Related Party Transaction [Line Items]

Equity instruments granted in period

25,000

Compensation for Serving as Chairman of Board | Board of Directors Chairman

Related Party Transaction [Line Items]

Option Granted Period

10 years

Number of vesting installments

2

Consulting and Advisory Agreement

Related Party Transaction [Line Items]

Stock options issued to purchase shares of common stock

36,000

Common stock price (usd per share)

$10

Common stock, vesting period

2 years

Consulting and advisory agreement expenses under stock option plan

0

76,220

430,600

Renewed Consulting and Advisory Agreement | Dr. Chaganti

Related Party Transaction [Line Items]

Consulting and advisory agreement expenses under stock option plan

341,000

0

0

USPTO Patent Issuance Agreement | Dr. Chaganti

Related Party Transaction [Line Items]

Agreement with related party, consulting fee

150,000

Agreement with related party, one-time payment required

50,000

Agreement with related party, percentage of net revenues required to be paid

1.00%

Number of patents

3

Subsequent Event | USPTO Patent Issuance Agreement | Dr. Chaganti

Related Party Transaction [Line Items]

Agreement with related party, consulting fee

$150,000

Number of patents

3